Rapid release softgel formulation

Abstract

Described herein are rapid releasing softgel capsule formulations, dosage forms, and methods for manufacturing and administration. In one embodiment, the rapid releasing softgel capsules rupture in about 3–9 minutes under laboratory conditions. Dosage forms comprising such capsules can provide rapid delivery of active pharmaceutical ingredients to subjects in need thereof.

Description

[0001]RAPID RELEASE SOFTGEL FORMULATION BACKGROUND Softgel capsules have gained popularity and acceptance due to their elegant and clear gelatin shells. Furthermore, softgel capsules are uniform, stable, dissolve relatively quickly, allow for liquid formulations, and are easier for most subjects to swallow. Softgel capsules are typically formed of a capsule shell encapsulating a liquid matrix fill. The matrix fill may be aqueous, or oil based, which is useful depending on the solubility of the active pharmaceutical ingredient (API). There is increased interest in developing softgel capsules that dissolve rapidly. What are needed are softgel capsules that readily dissolve or rupture and release the API rapidly. SUMMARY One embodiment described herein is a rapid releasing softgel capsule formulation, the formulation comprising: about 15–60% by mass of one or more film-forming polymers; about 1– 30% by mass of one or more disintegrating agents; about 5–30% by mass of one or more plasticizers or co-solvents; and about 10–45% by mass of one or more solvents. Optionally, the formulation further comprising about 1-20% by mass of one or more viscosity modifying polymers. In one aspect, the one or more film-forming polymers comprises gelatin, gelatin hydrolysates, collagen, carrageenans, or agars. In another aspect, the one or more film-forming polymers comprises gelatin having a Bloom value of about 50 Bloom to about 200 Bloom. In another aspect, the gelatin has a Bloom value of about 150 Bloom. In another aspect, the formulation comprises about 20–40% by mass of the one or more film-forming polymers. In another aspect, the one or more disintegrating agents comprises sodium starch glycolate, croscarmellose sodium, crospovidone, calcium silicate, magnesium aluminum silicate, or cross-linked alginic acid. In another aspect, the formulation comprises about 5–25% by mass of the one or more disintegrating agents. In another aspect, the formulation comprises about 8–12% by mass of the one or more disintegrating agents. In another aspect, the formulation comprises about 15–25% by mass of the one or more disintegrating agents. In another aspect, the one or more plasticizers or co- solvents comprises solutions of polyols, monosaccharides, disaccharides, oligosaccharides, blended hydrophilic molecules, glycerol, sorbitol, polyethylene glycols, or maltitol. In another aspect, the formulation comprises about 10–20% by mass of the one or more plasticizers or co- solvents. In another aspect, the one or more solvents comprises water. The formulation of claim 1, further comprising one or more of colorants, opacifiers, flavors or sweeteners, humectants, preservatives, coatings, viscosity modifiers, fillers or bulking agents, active pharmaceutical ingredients, viscosity modifying polymers, or buffering salts and acids. In another aspect, the formulation comprises about 0.01–10% by mass of one or more colorants comprising synthetic dyes, natural dyes, or a combination thereof. In another aspect, the formulation comprises about 0.01–1% by mass of one or more opacifiers comprising titanium dioxide, zinc oxide, calcium carbonate, or combinations thereof. In another aspect, the formulation comprises about 0.01–1% by mass of one or more flavors or sweeteners. In another aspect, the formulation comprises about 1–20% by mass of one or more viscosity modifying polymers. In another aspect, the formulation comprises 5–15% by mass of the one or more viscosity modifying polymers, or about 10% by mass of the one or more viscosity modifiers. In another aspect, the formulation comprises one or more viscosity modifying polymers comprising hydroxypropyl-methylcellulose, polyvinyl- pyrrolidone, polyvinyl alcohol, and dextran. In another aspect, the capsule ruptures within about 3–9 minutes in a USP Apparatus II at 37 °C. In another aspect, the capsule ruptures within about 5 minutes in a USP Apparatus II at 37 °C. Another embodiment described herein is a method for manufacturing a rapid releasing softgel capsule, the method comprising: preparing a gel mass composition comprising one or more film-forming polymers, one or more disintegrants, one or more plasticizers or co-solvents, and one or more solvents to form a gel mass, and optionally, one or more viscosity modifying polymers; heating the gel mass to create a homogenous and de-aerated gel mass; ageing the homogenous and de-aerated gel mass to create an aged gel mass; casting the aged gel mass into films or ribbons using heat-controlled drums or surfaces; transferring a homogenized fill solution to an encapsulation line; encapsulating the homogenized fill solution within the gel mass films or ribbons using rotary dye encapsulation to create a capsule; drying and finishing the capsule; optionally, coating the capsule with a coating and drying; and post processing and packaging. In one aspect, the gel mass comprises: about 15–60% by mass of the one or more film-forming polymers; about 1–30% by mass of the one or more disintegrants; about 5–30% by mass of the one or more plasticizers or co-solvents; and about 10–45% by mass of the one or more solvents. In another aspect, heating the gel mass in step (b) comprises a temperature of about 57–80 °C under vacuum for about 15–30 minutes to create the homogenous and de-aerated gel mass. In another aspect, ageing the homogenous and de-aerated gel mass in step (c) comprises a temperature of about 65–70 °C for about 12–48 hours to create the aged gel mass. In another aspect, the capsule is pre-stressed to increase the rupture rate. Another embodiment described herein is a rapid releasing softgel capsule manufactured by any of the methods described herein. Another embodiment described herein is a pharmaceutical dosage form comprising a rapid releasing softgel capsule and a matrix fill comprising one or more active pharmaceutical ingredients, wherein the rapid releasing softgel capsule ruptures within about 3–9 minutes in a USP Apparatus II at 37 °C and releases the matrix fill comprising the one or more active pharmaceutical ingredients. In one aspect, the dosage form ruptures within about 5 minutes in a USP Apparatus II at 37 °C. In another aspect, the rapid releasing softgel capsule comprises: about 15–60% by mass of the one or more film-forming polymers; about 1–30% by mass of the one or more disintegrants; about 5–30% by mass of the one or more plasticizers or co-solvents; and about 10–45% by mass of the one or more solvents. Another embodiment described herein is a pharmaceutical dosage form comprising a rapid releasing softgel capsule and an encapsulated tablet comprising one or more active pharmaceutical ingredients, wherein the rapid releasing softgel capsule ruptures within about 3– 9 minutes in a USP Apparatus II at 37 °C and releases the encapsulated tablet comprising the one or more active pharmaceutical ingredients. In one aspect, the dosage form ruptures within about 5 minutes in a USP Apparatus II at 37 °C. In another aspect, the rapid releasing softgel capsule comprises: about 15–60% by mass of the one or more film-forming polymers; about 1– 30% by mass of the one or more disintegrants; about 5–30% by mass of the one or more plasticizers or co-solvents; about 10–45% by mass of the one or more solvents; and optionally about 1-20% by mass of one or more viscosity modifying polymers. Another embodiment described herein is a method for rapidly delivering one or more active pharmaceutical ingredients to a subject in need thereof, the method comprising administering to the subject a pharmaceutical dosage form comprising a rapid releasing softgel capsule and a matrix fill comprising the one or more active pharmaceutical ingredients, wherein the rapid releasing softgel capsule ruptures within about 3–9 minutes following administration and releases the matrix fill comprising the one or more active pharmaceutical ingredients to the subject. In one aspect, the dosage form ruptures within about 5 minutes following administration. Another embodiment described herein is a method of treating a subject in need thereof with one or more active pharmaceutical ingredients, the method comprising administering to the subject a pharmaceutical dosage form comprising a rapid releasing softgel capsule and a matrix fill comprising the one or more active pharmaceutical ingredients, wherein the rapid releasing softgel capsule ruptures within about 3–9 minutes following administration and releases the matrix fill comprising the one or more active pharmaceutical ingredients to the subject. In one aspect, the dosage form ruptures within about 5 minutes following administration. DESCRIPTION OF THE DRAWINGS FIG. 1 shows a flow chart for an exemplary process for preparing a rapid releasing softgel capsule. FIG. 2 shows the results of a rupture test at 37 °C on experimental and control samples. FIG. 3 shows the results of a rupture test at 22 °C on experimental and control samples. FIG. 4 shows the results of a rupture test at 37 °C on experimental and control samples. FIG. 5A–B shows the results of a dissolution test at 37 °C on experimental and control samples. FIG. 5A shows rapid releasing capsules containing acetaminophen compared to controls. FIG. 5B shows dissolution of the acetaminophen control capsule in normal dissolution media and with media containing enzymes. DETAILED DESCRIPTION Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. For example, any nomenclatures used in connection with, and techniques of pharmaceutical formulation, medicinal chemistry, biochemistry, molecular biology, immunology, microbiology, genetics, cell and tissue culture, and protein and nucleic acid chemistry described herein are well known and commonly used in the art. In case of conflict, the present disclosure, including definitions, will control. Exemplary methods and materials are described below, although methods and materials similar or equivalent to those described herein can be used in practice or testing of the embodiments and aspects described herein. As used herein, the terms “amino acid,” “nucleotide,” “polynucleotide,” “vector,” “polypeptide,” and “protein” have their common meanings as would be understood by a biochemist of ordinary skill in the art. Standard single letter nucleotides (A, C, G, T, U) and standard single letter amino acids (A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y) are used herein. As used herein, the terms such as “include,” “including,” “contain,” “containing,” “having,” and the like mean “comprising.” The present disclosure also contemplates other embodiments “comprising,” “consisting essentially of,” and “consisting of” the embodiments or elements presented herein, whether explicitly set forth or not. As used herein, the term “a,” “an,” “the” and similar terms used in the context of the disclosure (especially in the context of the claims) are to be construed to cover both the singular and plural unless otherwise indicated herein or clearly contradicted by the context. In addition, “a,” “an,” or “the” means “one or more” unless otherwise specified. As used herein, the term “or” can be conjunctive or disjunctive. As used herein, the term “and / or” refers to both the conjuctive and disjunctive. As used herein, the term “substantially” means to a great or significant extent, but not completely. As used herein, the term “about” or “approximately” as applied to one or more values of interest, refers to a value that is similar to a stated reference value, or within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, such as the limitations of the measurement system. In one aspect, the term “about” refers to any values, including both integers and fractional components that are within a variation of up to ± 10% of the value modified by the term “about.” Alternatively, “about” can mean within 3 or more standard deviations, per the practice in the art. Alternatively, such as with respect to biological systems or processes, the term “about” can mean within an order of magnitude, in some embodiments within 5-fold, and in some embodiments within 2-fold, of a value. As used herein, the symbol “~” means “about” or “approximately.” All ranges disclosed herein include both points as discrete values as well as all integers and fractions specified within the range. For example, a range of 0.1–2.0 includes 0.1, 0.2, 0.3, 0.4 . . . 2.0. If the end points are modified by the term “about,” the range specified is expanded by a variation of up to ±10% of any value within the range or within 3 or more standard deviations, including the end points. As used herein, the terms “control,” or “reference” are used herein interchangeably. A “reference” or “control” level may be a predetermined value or range, which is employed as a baseline or benchmark against which to assess a measured result. “Control” also refers to control experiments or control cells. As used herein, “treatment” or “treating” refers to prophylaxis of, preventing, suppressing, repressing, reversing, alleviating, ameliorating, or inhibiting the progress of biological process including a disorder or disease, or completely eliminating a disease. A treatment may be either performed in an acute or chronic way. The term “treatment” also refers to reducing the severity of a disease or symptoms associated with such disease prior to affliction with the disease. “Repressing” or “ameliorating” a disease, disorder, or the symptoms thereof involves administering a cell, composition, or compound described herein to a subject after clinical appearance of such disease, disorder, or its symptoms. “Prophylaxis of” or “preventing” a disease, disorder, or the symptoms thereof involves administering a cell, composition, or compound described herein to a subject prior to onset of the disease, disorder, or the symptoms thereof. “Suppressing” a disease or disorder involves administering a cell, composition, or compound described herein to a subject after induction of the disease or disorder thereof but before its clinical appearance or symptoms thereof have manifest. As used herein, the term “prophylaxis” refers to preventing or reducing the progression of a disorder, either to a statistically significant degree or to a degree detectable by a person of ordinary skill in the art. As used herein, the terms “effective amount” or “therapeutically effective amount,” refers to a substantially non-toxic, but sufficient amount of an action, agent, composition, or cell(s) being administered to a subject that will prevent, treat, or ameliorate to some extent one or more of the symptoms of the disease or condition being experienced or that the subject is susceptible to contracting. The result can be the reduction or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. An effective amount may be based on factors individual to each subject, including, but not limited to, the subject’s age, size, type or extent of disease, stage of the disease, route of administration, the type or extent of supplemental therapy used, ongoing disease process, and type of treatment desired. As used herein, the terms “inhibit,” “inhibition,” or “inhibiting” refer to the reduction or suppression of a given biological process, condition, symptom, disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process. As used herein, the term “subject” refers to an animal. Typically, the subject is a mammal. A subject also refers to primates (e.g., humans, male or female; infant, adolescent, or adult), non- human primates, rats, mice, rabbits, pigs, cows, sheep, goats, horses, dogs, cats, fish, birds, and the like. In one embodiment, the subject is a primate. In one embodiment, the subject is a human. As used herein, a subject is “in need of treatment” if such subject would benefit biologically, medically, or in quality of life from such treatment. A subject in need of treatment does not necessarily present symptoms, particular in the case of preventative or prophylaxis treatments. The term “active ingredient” or “active pharmaceutical ingredient” or “active pharmaceutical agent” or “API” or “drug” as used herein refers to an agent, active ingredient, compound, or substance, compositions, or mixtures thereof, that provide a pharmacological, often beneficial, effect. Reference to a specific active ingredient includes, where appropriate, the active ingredient and any of its pharmaceutically acceptable salts or esters. In some embodiments, one or more active pharmaceutical ingredients may be incorporated into a matrix fill as described herein. In some embodiments, one or more active pharmaceutical ingredients may be incorporated into a pressed tablet as described herein. In some embodiments, one or more active pharmaceutical ingredients may be incorporated into a softgel capsule formulation as described herein. The terms “dosage” or “dose” denote any form of the active ingredient formulation or composition that contains an amount sufficient to initiate or produce a therapeutic effect with at least one or more administrations. The dosage form used herein is for oral administration. The preferred oral dosage forms are soft capsules. As used herein, the term “pharmaceutical composition” refers to a composition comprising at least on active ingredient, nutraceutical, nutritional, or vitamin. In some embodiments described herein, a pharmaceutical composition comprises a soft capsule shell having been formed into a capsule, for example, using rotary die encapsulation comprising one or more polyunsaturated fatty acids, optionally with one or more vitamins, antioxidants, or other active ingredients. As used herein, the term “formulation” or “composition” refers to the active pharmaceutical ingredient or drug in combination with pharmaceutically acceptable excipients. This includes orally administrable formulations as well as formulations administrable by other means. “Formulation” and “composition” are used interchangeably herein. As used herein, the term “room temperature” refers to common ambient temperatures found in pharmaceutical laboratories ranging from about 20 °C to about 27 °C. As used herein, the terms “weight percent,” “% wt,” “mass percent,” or “percent mass” refer to the mass of a specific component of a composition as a percentage of the total mass of the composition (assumed to be 100%). The terms “percent (or %). . . wet mass” refers to the mass percentage of a composition that contains a mass of solvent, typically water, in the composition. Likewise, “percent (or %). . . dry mass” refers to the mass percentage of a composition containing only or predominately dry ingredients. As used herein, the term “wet shell mass,” or “wet capsule mass” refer to the mass of the capsule during formulation and manufacturing but before drying. During the manufacturing process, softgel capsules are dried and a portion of the solvent (typically water) evaporates. This increases the integrity and rigidity of the capsule shell. Consequently, the relative mass percentage of the non-fugative components increases proportionate to the decrease in the amount of solvent that has evaporated during drying. It is difficult to measure the “dry shell mass” or “dry shell mass percentage,” but these values can be estimated based on the difference in mass of the capsule immediately after manufacturing and after drying, assuming that the difference in mass is solely due to solvent evaporation. As used herein, the terms “release” or “releasing” refer to the dicharge of a portion of the active ingredient from a softgel matrix into a medium, such as a buffer or stomach fluid. As used herein, the terms “rapid release” or “rapid releasing” refer to a softgel capsule that rapidly releases a portion of the active ingredient from a softgel matrix fill into a medium as compared to a typical softgel capsule. In one aspect, “rapid releasing” refers to a softgel capsule that rapidly releases a portion of the active ingredient from the matrix fill into the medium within about 0.5 min, 1 minute, 2 min, 3 min, 4 min, 5 min, 6 min, 7 min, 8 min, 9 min, 10 min, 15 min, 20 min, or 30 min. One embodiment described herein is a rapid releasing soft capsule. A used herein, the term “rupture” refers to the initial opening of a softgel capsule where the contents begin to release from the matrix and dissolve into the medium. As used herein, the terms “rapid rupture” or “rapid rupturing” refer to a softgel capsule that rapidly ruptures in a medium as compared to a standard soft gel capsule. In one aspect, “rapid rupturing” refers to a softgel capsule that rapidly releases a portion of the active ingredient from the matrix fill into the medium within about 0.5 min, 1 minute, 2 min, 3 min, 4 min, 5 min, 6 min, 7 min, 8 min, 9 min, 10 min, 15 min, 20 min, or 30 min. One embodiment described herein is a rapid rupturing soft capsule. As used herein, the term “dissolution” refers to the solvation of a softgel capsule. Without being bound by any theory, a softgel capsule shell begins slowly dissolving upon entering a medium such as a buffer or stomach fluid. As the capsule shell dissolves, the capsule typically ruptures at a point of weakness, such as a manufacturing seam. The capsule matrix begins to release the fill from the initial rupture opening while the medium enters the rupture and begins solvating the matrix remaining in the capsule. Simultaneously, the capsule shell continues to dissolve, and the rupture opening grows in size, while the matrix is released. Over a period of time, both the matrix and capsule shell are completely solvated, and the capsule is dissolved. As used herein, the terms “rapid dissolution” or “rapid dissolving” refer to a softgel capsule that rapidly dissolves in a medium as compared to a to a standard soft gel capsule. In one aspect, “rapid dissolving” refers to a softgel capsule that rapidly dissolves within about 0.5 min, 1 min, 2 min, 3 min, 4 min, 5 min, 6 min, 7 min, 8 min, 9 min, 10 min, 15 min, 20 min, 25 min, 30 min, 35 min, 40 min, 45 min, 50 min, 55 min, or 60 min. One embodiment described herein is a rapid dissolving soft capsule. As used herein, the terms “typical softgel capsule” or “standard softgel capsule” refer to a softgel capsule having a shell that contains one or more film forming polymers (e.g., gelatin), a plasticizer (e.g., glycerol), and water and that is manufactured by rotary die encapsulation. Typical softgel capsules do not contain disintegrating agents as described herein. Typical softgel capsules containing an aqueous (non-oil) fill generally rupture in a buffer medium within 15–20 minutes and completely dissolve within 30–45 min. Typical softgel capsules also do not contain viscosity modifying polymers due to their specific formulation requirements. The main purpose of softgel capsules is to provide an easy-to- swallow dosage form that delivers the API in a consistent and controlled manner. The presence of viscosity modifying polymers may interfere with the flow properties of the liquid or semi-solid core, making it difficult to fill the capsules uniformly and consistently. Moreover, viscosity modifying polymers may affect the dissolution and bioavailability of the API, which can impact the efficacy and pharmacokinetics of the drug. For example, it is well known that gelatin used in softgel capsules is recognized for its excellent gelling and film-forming properties, making it an ideal choice for encapsulation purposes. Viscosity modifying polymers, on the other hand, may not always be compatible with gelatin in terms of physical and chemical properties. Depending on amount of viscosity modifying polymer, it may not blend well with gelatin, leading to issues such as phase separation, instability, or compromised capsule integrity. As such, viscosity modifying polymer when improperly added to the shell composition may reduce its stability. Therefore, typical softgel capsules are formulated without the addition of viscosity modifying polymers. As used herein, rupture testing, dissolution testing, comparative dissolution, and similar experiments were conducted in compliance with and according to protocols established by the United States Pharmacopeia (USP), including USP Disintegration Method !701" and USP General Chapter !2040", which are incorporated by reference herein for such teachings. Specific apparata are described in USP General Chapter !711" Dissolution and consists of Apparatus I – Basket Apparatus; Method II – Paddle Apparatus; Method III – Reciprocating Cylinder; and Method IV – Flow-Through Cell. See USP General Chapter !711" DISSOLUTION, Stage 6 Harmonization, The United States Pharmacopeial Convention (2011), which is incorporated by reference herein for such teachings. As used herein, the term “film-forming polymer” refers to a water-soluble polymer agent capable of forming a film that enhances the integrity of a softgel capsule shell. Typical film forming polymers are gelatin, gelatin hydrolysates, collagen, or the like. As used herein, the term “plasticizer” refers to an agent that adds extensibility, dispensability, flexibility, elasticity, rigidity, pliability, and / or enhanced mechanical properties to a softgel capsule shell by interacting with the film-forming polymer. The plasticizer can minimize brittleness and cracking of the softgel capsule shell. As used herein, the term “co-solvent” refers to an agent that aids in the solubility of a softgel capsule. As used herein, the term “disintegrant” or “disintegrating agent” refers to an agent that promotes the degradation, disintegration, or rupturing of a softgel capsule into smaller fragments when in an aqueous environment, thereby increasing the available surface area and promoting a more rapid release of the capsule’s matrix fill components. As used herein, the term “viscosity modifying polymer” refers to an agent that modifies the viscosity of a softgel capsule, thereby increasing the stability of the capsule without retarding the speed of release of the capsule’s matrix fill components. Viscosity modifying polymer may be a viscosity reducing agent that is used to decrease the viscosity or thickness of the capsule. Viscosity modifying polymer (i.e. water-soluble polymer and / or with low molecular weight) described herein thus functions as a viscosity reducing agent instead of a binding agent. Other class of commonly known viscosity-reducing excipients are L-Arginine, L-Phenylalanine, L- Ornithine monohydrochloride, Benzenesulfonic acid, Pyridoxine hydrochloride, and Thiamine phosphoric acid ester chloride dihydrate. As used herein, the term “solvent” refers to an aqueous agent used to solubilize the various components of a softgel capsule formulation. As used herein, the term “Cmax” as used herein refers to the maximum observed blood (plasma, serum, or whole blood) concentration or the maximum blood concentration calculated or estimated from a concentration to time curve and is expressed in units of mg / L or ng / mL, as applicable. As used herein, the term “Cmin” refers to the minimum observed blood (plasma, serum, or whole blood) concentration or the minimum blood concentration calculated or estimated from a concentration to time curve and is expressed in units of mg / L or ng / mL, as applicable. As used herein, the term “Cavg” refers to the blood (plasma, serum, or whole blood) concentration of the drug within the dosing interval, is calculated as AUC / dosing interval, and is expressed in units of mg / L or ng / mL, as applicable. As used herein, the term “Tmax” refers to the time after administration at which Cmax occurs and is expressed in units of hours (h) or minutes (min), as applicable. As used herein, the term “AUC0→τ” refers to area under the blood (plasma, serum, or whole blood) concentration versus time curve from time zero to time tau (τ) over a dosing interval at steady state, where tau is the length of the dosing interval, and is expressed in units of h·mg / L or h·ng / mL, as applicable. For example, the term AUC0→12as used herein refers to the area under the concentration versus time curve from 0 to 12 hours. As used herein, the term “AUC0→∞” refers to the area under the blood (plasma, serum, or whole blood) concentration versus time curve from time 0 hours to infinity and is expressed in units of h·mg / L or h·ng / mL, as applicable. As used herein, the term “AUCoverall” refers to the combined area under the blood (plasma, serum, or whole blood) concentration versus time curve, and is expressed in units of h·mg / L (or h·ng / mL) for at least one or more doses of the pharmaceutical compositions described herein. In one aspect, the “AUCoverall” refers to the combined area under the blood concentration versus time curve for at least two doses of the pharmaceutical compositions described herein. As used herein, the term “gel reactor” refers to a specialized vessel or apparatus used in the production of softgel capsule. It is designed to facilitate the mixing, blending, and formation of gels by providing controlled conditions for the gelation process. The gel reactor typically comprises a container or tank that can hold the gel formulation. It is equipped with mixing mechanisms, such as impellers, blades, or agitators, that are responsible for creating the necessary shear forces to mix and disperse the gel components. The design of the reactor may vary depending on the specific requirements (i.e., gelation kinetics and viscosity) of the gel formulation and the desired end product. Capsule Compositions One embodiment described herein is a formulation for a rapid releasing softgel capsule. An exemplary rapid releasing capsule composition is shown in Table 1. Table 1: Exemplary Rapid Releasing Capsule Shell Components Component Function Exemplary Components Mass Range (%) Gelatin, gelatin carrageenan, agars Sodium starch glycolate, croscarmellose sodium, Disintegrating Agents Super disintegrants crospovidone, calcium silicate, magnesium 1–30 aluminum silicate, and cross-linked alginic acid Extensibility, Polyols, Dispensability, monosaccharides, disaccharides, Plasticizers Flexibility, Elasticity, Rigidity oligosaccharides, blended 5–30 and Mechanical hydrophilic molecules, Properties glycerol, sorbitol, polyethylene glycols Cosolvents (optional) Aids solubility Maltitol (hydrogenated glucose syrup; Lycasin®) 5–25 Water Solvent Purified Water 10–45 (q.s. to reach 100%) Colorant (optional) Color shell Natural and synthetic FD&C colors 0.01–10 Opacifiers (optional) Opacify shell Titanium dioxide 0.01–1 Flavorants (optional) Flavor shell Orange, grape, cherry, sweeteners, etc. 0.01–1 Hydroxypropyl- Viscosity modifying Viscosity reducing methylcellulose (HPMC) polymer (optional) agent Polyvinyl- pyrrolidone 1-20 (PVP), Polyvinyl alcohol (PVA), and Dextran Total Shell Mass Percentage (%) 100 Theoretical Total Shell Weight (Dry shell) 1–3000 mg Examples of film-forming polymers that are useful for creating soft capsules as described herein comprise gelatins, including acid bone gelatin, lime bone gelatin, beef skin gelatin, pig skin gelatin, chicken skin gelatin, fish gelatin, acid hide gelatin, gelatin hydrolysate, collagens, or combinations thereof. The gelatin can be Type A or Type B gelatin. Type A gelatin is derived from the acid hydrolysis of collagen (e.g., acid bone gelatin or pig skin gelatin), while Type B gelatin (e.g., lime bone gelatin) is derived from the alkaline hydrolysis of collagen. Traditionally, bovine bones and skins are used as raw materials for manufacturing Type A and Type B gelatin, while porcine skins are used extensively for manufacturing Type A gelatin. In addition, at neutral pH values, Type A gelatins (acid processed gelatins) are typically net cationic (e.g., isoelectric point of about 7–9) and Type B gelatins (alkali processed gelatins) are typically net anionic (e.g., isoelectric point of about 4.5–5.3). Type A gelatin typically has higher plasticity and elasticity than type B gelatin; type B gelatin typically has higher gel strength than type A gelatin. The strength of gelatin compositions is typically defined by their Bloom strength or grade. The Bloom test determines the weight (in grams) needed by a 0.5-inch diameter probe to deflect the surface of a gel 4 mm without breaking it. The result is expressed as “Bloom” or “Bloom strength.” The soft capsules described herein utilize gelatins with Bloom strengths in the range of about 20 Bloom to about 400 Bloom, including each integer within the specified range. In one embodiment, Bloom strengths for soft capsules described herein are about 50 Bloom to about 250 Bloom including each integer within the specified range. In some embodiments, the gelatin Bloom strenght is about 50 Bloom, about 80 Bloom, about 100 Bloom, about 120 Bloom, about 150 Bloom, about 180 Bloom, about 200 Bloom, or about 250 Bloom. In one embodiment, the gelatin Bloom strength is 100 Bloom. In another embodiment, the gelatin Bloom strength is 150 Bloom. In another embodiment, the gelatin Bloom strength is 175 Bloom. In another embodiment, the gelatin Bloom strength is 200 Bloom. Examples of film-forming polymers that are useful for creating non-animal / non-gelatin soft capsules described herein are kappa carrageenan, iota carrageenan, lambda carrageenan, or combinations thereof. Examples of film-forming anionic polysaccharides, as described herein, comprise polygalacturonic acid, carboxymethyl pullulan, carboxymethyl cellulose, hyaluronic acid, cellulose phthalate, cellulose succinate, alginate, sodium alginate, and pectin, acrylic and methacrylate acid copolymers, cellulose acetate phthalate (CAP), cellulose acetate butyrate, hydroxypropylmethylcellulose phthalate (HPMCP), algenic acid salts such as sodium or potassium alginate, or shellac. Poly(methacylic acid-co-methyl methacrylate) anionic copolymers based on methacrylic acid and methyl methacrylate are particularly stable and are preferred in some embodiments. Poly(meth)acrylates (methacrylic acid copolymer), available under the trade name EUDRAGIT®(Evonik Industries AG, Essen, Germany), are provided as powder or aqueous dispersions. In one aspect, the methacrylic acid copolymer can be EUDRAGIT®L 30 D-55; EUDRAGIT®L 100-55; EUDRAGIT®L 100; EUDRAGIT®L 12.5; EUDRAGIT®S 100; EUDRAGIT®S 12.5; EUDRAGIT®FS 30 D; EUDRAGIT®E 100; EUDRAGIT®E 12.5; EUDRAGIT®E PO; EUDRAGIT®RL 100; EUDRAGIT®RL PO; EUDRAGIT®RL 30 D; EUDRAGIT®RL 12.5; EUDRAGIT®RS 100; EUDRAGIT®RS PO; EUDRAGIT®RS 30 D; EUDRAGIT®RS 12.5; EUDRAGIT®NE 30 D; EUDRAGIT®NE 40 D; EUDRAGIT®NM 30 D; or other poly(meth)acrylate polymers. Film-forming polymers typically comprise a mass percentage of about 15–60% of the total wet mass of a shell, including each integer and fraction within the specified range. For example, one or more film-forming polymers may comprise a mass percentage of about 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, or 60%, or about 15–20%, 15–25%, 15–30%, 15–35%, 15– 40%, 15–45%, 15–50%, 15–55%, 20–25%, 20–30%, 20–35%, 20–40%, 20–45%, 20–50%, 20– 55%, 20–60%, 25–30%, 25–35%, 25–45%, 25–50%, 25–55%, 25–60%, 30–35%, 30–40%, 30– 45%, 30–50%, 30–55%, 30–60%, 35–40%, 35–45%, 35–50%, 35–55%, 35–60%, 40–45%, 40– 50%, 40–55%, 40–60%, 45–50%, 45–55%, 45–60%, 50–55%, 50–60%, or 55–60% of the total wet mass of a shell, including each integer and fraction within these specified values and ranges. In some embodiments, one or more film-forming polymers may comprise a mass percentage of about 20–40% of the total wet mass of a shell, including each integer and fraction within this specified range. In one non-limiting embodiment, one or more film-forming polymers may comprise a mass percentage of about 35–45%, or about 35–40%, of the total wet mass of a shell, including each integer and fraction within these specified ranges. Plasticizers and / or co-solvents that are useful for creating soft capsules as described herein are maltitol (hydrogenated corn syrup; e.g., Lycasin®, Roquette), sorbitol, glycerol, partially dehydrated sorbitol, a blend of D-sorbitol, 1,4-sorbitan, mannitol, and water; e.g., Sorbitol Special®(SPI Pharma); Anidrisorb®or Polysorb®, (Roquette), corn syrup, xylitol, mannitol, propylene glycol, low molecular weight polyethylene glycols, poly-alcohols with 3 to 6 carbon atoms, or a combination thereof. Plasticizers and / or co-solvents typically comprise a mass percentage of about 5–30% of the total wet mass of a shell, including each integer and fraction within the specified range. For example, one or more plasticizers or co-solvents may comprise a mass percentage of about 5%, 8%, 10%, 12%, 15%, 18%, 20%, 22%, 25%, 28%, or 30%, or about 5– 8%, 5–10%, 5–12%, 5–15%, 5–18%, 5–20%, 5–22%, 5–25%, 5–28%, 8–10%, 8–12%, 8–15%, 8–18%, 8–20%, 8–22%, 8–25%, 8–28%, 8–30%, 10–12%, 10–15%, 10–18%, 10–20%, 10–22%, 10–25%, 10–28%, 10–30%, 12–15%, 12–18%, 12–20%, 12–22%, 12–25%, 12–28%, 12–30%, 15–18%, 15–20%, 15–22%, 15–25%, 15–28%, 15–30%, 18–20%, 18–22%, 18–25%, 18–28%, 18–30%, 20–22%, 20–25%, 20–28%, 20–30%, 22–25%, 22–28%, 22–30%, 25–28%, 25–30%, or 28–30% of the total wet mass of a shell, including each integer and fraction within these specified values and ranges. In some embodiments, one or more plasticizers or co-solvents may comprise a mass percentage of about 10–20% of the total wet mass of a shell, including each integer and fraction within this specified range. In one non-limiting embodiment, one or more plasticizers or co-solvents may comprise a mass percentage of about 15–20%, or about 15–18%, of the total wet mass of a shell, including each integer and fraction within these specified ranges. The weight ratio between the film-forming polymer, plasticizer and / or co-solvent, and solvent is adjusted so that the gel mass is flowable and not too viscous and can be made into soft capsules using rotary die encapsulation methods. Disintegrating agents that are useful for creating soft capsules as described herein include, but are not limited to, sodium starch glycolate (“SSG”), croscarmellose sodium, crospovidone, calcium silicate, magnesium aluminum silicate, cross-linked alginic acid, or combinations thereof. In one aspect, the disintegrating agent is sodium starch glycolate. Disintegrating agents typically comprise a mass percentage of about 1–40% of the total wet mass of a shell, including each integer and fraction within the specified range. For example, one or more disintegrating agents may comprise a mass percentage of about 1%, 2%, 2.5%, 5%, 7.5%, 8%, 8.5%, 9%, 9.5%, 10%, 10.5%, 11%, 11.5%, 12%, 12.5%, 13%, 13.5%, 15%, 17.5%, 18%, 18.5%, 19%, 19.5%, 20%, 20.5%, 21%, 21.5%, 22%, 22.5%, 25%, 30%, 35%, or 40%, or about 1–2%, 1–2.5%, 1–5%, 1–7.5%, 1–8%, 1–8.5%, 1–9%, 1–9.5%, 1–10%, 1–10.5%, 1–11%, 1– 11.5%, 1–12%, 1–12.5%, 1–13%, 1–13.5%, 1–15%, 1–17.5%, 1–18%, 1–18.5%, 1–19%, 1– 19.5%, 1–20%, 1–20.5%, 1–21%, 1–21.5%, 1–22%, 1–22.5%, 1–25%, 1–30%, 1–35%, 2–2.5%, 2–5%, 2–7.5%, 2–8%, 2–8.5%, 2–9%, 2–9.5%, 2–10%, 2–10.5%, 2–11%, 2–11.5%, 2–12%, 2– 12.5%, 2–13%, 2–13.5%, 2–15%, 2–17.5%, 2–18%, 2–18.5%, 2–19%, 2–19.5%, 2–20%, 2– 20.5%, 2–21%, 2–21.5%, 2–22%, 2–22.5%, 2–25%, 2–30%, 2–35%, 2–40%, 2.5–5%, 2.5–7.5%, 2.5–8%, 2.5–8.5%, 2.5–9%, 2.5–9.5%, 2.5–10%, 2.5–10.5%, 2.5–11%, 2.5–11.5%, 2.5–12%, 2.5–12.5%, 2.5–13%, 2.5–13.5%, 2.5–15%, 2.5–17.5%, 2.5–18%, 2.5–18.5%, 2.5–19%, 2.5– 19.5%, 2.5–20%, 2.5–20.5%, 2.5–21%, 2.5–21.5%, 2.5–22%, 2.5–22.5%, 2.5–25%, 2.5–30%, 2.5–35%, 2.5–40%, 5–7.5%, 5–8%, 5–8.5%, 5–9%, 5–9.5%, 5–10%, 5–10.5%, 5–11%, 5–11.5%, 5–12%, 5–12.5%, 5–13%, 5–13.5%, 5–15%, 5–17.5%, 5–18%, 5–18.5%, 5–19%, 5–19.5%, 5– 20%, 5–20.5%, 5–21%, 5–21.5%, 5–22%, 5–22.5%, 5–25%, 5–30%, 5–35%, 5–40%, 7.5–8%, 7.5–8.5%, 7.5–9%, 7.5–9.5%, 7.5–10%, 7.5–10.5%, 7.5–11%, 7.5–11.5%, 7.5–12%, 7.5–12.5%, 7.5–13%, 7.5–13.5%, 7.5–15%, 7.5–17.5%, 7.5–18%, 7.5–18.5%, 7.5–19%, 7.5–19.5%, 7.5– 20%, 7.5–20.5%, 7.5–21%, 7.5–21.5%, 7.5–22%, 7.5–22.5%, 7.5–25%, 7.5–30%, 7.5–35%, 7.5– 40%, 8–8.5%, 8–9%, 8–9.5%, 8–10%, 8–10.5%, 8–11%, 8–11.5%, 8–12%, 8–12.5%, 8–13%, 8– 13.5%, 8–15%, 8–17.5%, 8–18%, 8–18.5%, 8–19%, 8–19.5%, 8–20%, 8–20.5%, 8–21%, 8– 21.5%, 8–22%, 8–22.5%, 8–25%, 8–30%, 8–35%, 8–40%, 8.5–9%, 8.5–9.5%, 8.5–10%, 8.5– 10.5%, 8.5–11%, 8.5–11.5%, 8.5–12%, 8.5–12.5%, 8.5–13%, 8.5–13.5%, 8.5–15%, 8.5–17.5%, 8.5–18%, 8.5–18.5%, 8.5–19%, 8.5–19.5%, 8.5–20%, 8.5–20.5%, 8.5–21%, 8.5–21.5%, 8.5– 22%, 8.5–22.5%, 8.5–25%, 8.5–30%, 8.5–35%, 8.5–40%, 9–9.5%, 9–10%, 9–10.5%, 9–11%, 9– 11.5%, 9–12%, 9–12.5%, 9–13%, 9–13.5%, 9–15%, 9–17.5%, 9–18%, 9–18.5%, 9–19%, 9– 19.5%, 9–20%, 9–20.5%, 9–21%, 9–21.5%, 9–22%, 9–22.5%, 9–25%, 9–30%, 9–35%, 9–40%, 9.5–10%, 9.5–10.5%, 9.5–11%, 9.5–11.5%, 9.5–12%, 9.5–12.5%, 9.5–13%, 9.5–13.5%, 9.5– 15%, 9.5–17.5%, 9.5–18%, 9.5–18.5%, 9.5–19%, 9.5–19.5%, 9.5–20%, 9.5–20.5%, 9.5–21%, 9.5–21.5%, 9.5–22%, 9.5–22.5%, 9.5–25%, 9.5–30%, 9.5–35%, 9.5–40%, 10–10.5%, 10–11%, 10–11.5%, 10–12%, 10–12.5%, 10–13%, 10–13.5%, 10–15%, 10–17.5%, 10–18%, 10–18.5%, 10–19%, 10–19.5%, 10–20%, 10–20.5%, 10–21%, 10–21.5%, 10–22%, 10–22.5%, 10–25%, 10– 30%, 10–35%, 10–40%, 10.5–11%, 10.5–11.5%, 10.5–12%, 10.5–12.5%, 10.5–13%, 10.5– 13.5%, 10.5–15%, 10.5–17.5%, 10.5–18%, 10.5–18.5%, 10.5–19%, 10.5–19.5%, 10.5–20%, 10.5–20.5%, 10.5–21%, 10.5–21.5%, 10.5–22%, 10.5–22.5%, 10.5–25%, 10.5–30%, 10.5–35%, 10.5–40%, 11–11.5%, 11–12%, 11–12.5%, 11–13%, 11–13.5%, 11–15%, 11–17.5%, 11–18%, 11–18.5%, 11–19%, 11–19.5%, 11–20%, 11–20.5%, 11–21%, 11–21.5%, 11–22%, 11–22.5%, 11–25%, 11–30%, 11–35%, 11–40%, 11.5–12%, 11.5–12.5%, 11.5–13%, 11.5–13.5%, 11.5– 15%, 11.5–17.5%, 11.5–18%, 11.5–18.5%, 11.5–19%, 11.5–19.5%, 11.5–20%, 11.5–20.5%, 11.5–21%, 11.5–21.5%, 11.5–22%, 11.5–22.5%, 11.5–25%, 11.5–30%, 11.5–35%, 11.5–40%, 12–12.5%, 12–13%, 12–13.5%, 12–15%, 12–17.5%, 12–18%, 12–18.5%, 12–19%, 12–19.5%, 12–20%, 12–20.5%, 12–21%, 12–21.5%, 12–22%, 12–22.5%, 12–25%, 12–30%, 12–35%, 12– 40%, 12.5–13%, 12.5–13.5%, 12.5–15%, 12.5–17.5%, 12.5–18%, 12.5–18.5%, 12.5–19%, 12.5– 19.5%, 12.5–20%, 12.5–20.5%, 12.5–21%, 12.5–21.5%, 12.5–22%, 12.5–22.5%, 12.5–25%, 12.5–30%, 12.5–35%, 12.5–40%, 13–13.5%, 13–15%, 13–17.5%, 13–18%, 13–18.5%, 13–19%, 13–19.5%, 13–20%, 13–20.5%, 13–21%, 13–21.5%, 13–22%, 13–22.5%, 13–25%, 13–30%, 13– 35%, 13–40%, 13.5–15%, 13.5–17.5%, 13.5–18%, 13.5–18.5%, 13.5–19%, 13.5–19.5%, 13.5– 20%, 13.5–20.5%, 13.5–21%, 13.5–21.5%, 13.5–22%, 13.5–22.5%, 13.5–25%, 13.5–30%, 13.5– 35%, 13.5–40%, 15–17.5%, 15–18%, 15–18.5%, 15–19%, 15–19.5%, 15–20%, 15–20.5%, 15– 21%, 15–21.5%, 15–22%, 15–22.5%, 15–25%, 15–30%, 15–35%, 15–40%, 17.5–18%, 17.5– 18.5%, 17.5–19%, 17.5–19.5%, 17.5–20%, 17.5–20.5%, 17.5–21%, 17.5–21.5%, 17.5–22%, 17.5–22.5%, 17.5–25%, 17.5–30%, 17.5–35%, 17.5–40%, 18–18.5%, 18–19%, 18–19.5%, 18– 20%, 18–20.5%, 18–21%, 18–21.5%, 18–22%, 18–22.5%, 18–25%, 18–30%, 18–35%, 18–40%, 18.5–19%, 18.5–19.5%, 18.5–20%, 18.5–20.5%, 18.5–21%, 18.5–21.5%, 18.5–22%, 18.5– 22.5%, 18.5–25%, 18.5–30%, 18.5–35%, 18.5–40%, 19–19.5%, 19–20%, 19–20.5%, 19–21%, 19–21.5%, 19–22%, 19–22.5%, 19–25%, 19–30%, 19–35%, 19–40%, 19.5–20%, 19.5–20.5%, 19.5–21%, 19.5–21.5%, 19.5–22%, 19.5–22.5%, 19.5–25%, 19.5–30%, 19.5–35%, 19.5–40%, 20–20.5%, 20–21%, 20–21.5%, 20–22%, 20–22.5%, 20–25%, 20–30%, 20–35%, 20–40%, 20.5– 21%, 20.5–21.5%, 20.5–22%, 20.5–22.5%, 20.5–25%, 20.5–30%, 20.5–35%, 20.5–40%, 21– 21.5%, 21–22%, 21–22.5%, 21–25%, 21–30%, 21–35%, 21–40%, 21.5–22%, 21.5–22.5%, 21.5– 25%, 21.5–30%, 21.5–35%, 21.5–40%, 22–22.5%, 22–25%, 22–30%, 22–35%, 22–40%, 22.5– 25%, 22.5–30%, 22.5–35%, 22.5–40%, 25–30%, 25–35%, 25–40%, 30–35%, 30–40%, or 35– 40% of the total wet mass of a shell, including each integer and fraction within these specified values and ranges. In some embodiments, one or more disintegrating agents may comprise a mass percentage of about 1–30%, about 5–25%, about 8–12%, or about 15–25% of the total wet mass of a shell, including each integer and fraction within these specified ranges. In some embodiments, one or more disintegrating agents may comprise a mass percentage of up to about 10%, about 15%, about 20%, or about 30% of the total wet mass of a shell. In one non-limiting embodiment, one or more disintegrating agents may comprise a mass percentage of about 8– 10%, or about 8.5–9.5%, of the total wet mass of a shell, including each integer and fraction within these specified ranges. In some embodiments, the solvent comprises about 10% to about 45% by mass of the softgel capsule composition, including all integers and fractions within the specified range. In one embodiment, the solvent is water (e.g., purified water and / or extra purified water). The quantity of water in the composition varies depending on the quantities of the other ingredients. For example, the quantity of additional ingredients such as opacifiers, colorants, flavorings, or other excipients can change the percentage of water present in the composition. In one embodiment, the weight percentage of water is as much as suffices to bring the total mass percentage to 100% (i.e., quantum sufficiat; q.s.). In another embodiment, the water comprises about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, or about 45% by mass of the softgel capsule composition. In another embodiment, water comprises about 35% to about 40% of the softgel capsule composition. In one embodiment, water comprises about 37% by mass of the composition. The solvent typically comprises a mass percentage of about 10–45% of the total wet mass of a shell, including each integer and fraction within this specified range. For example, the solvent may comprise a mass percentage of about 10%, 15%, 20%, 25%, 30%, 35%, 40%, or 45%, or about 10–15%, 10–20%, 10–25%, 10–30%, 10–35%, 10–40%, 15–20%, 15–25%, 15– 30%, 15–35%, 15–40%, 15–45%, 20–25%, 20–30%, 20–35%, 20–40%, 20–45%, 25–30%, 25– 35%, 25–40%, 25–45%, 30–35%, 30–40%, 30–45%, 35–40%, 35–45%, or 40–45% of the total wet mass of a shell, including each integer and fraction within these specified values and ranges. In some embodiments, the solvent may comprise a mass percentage of about 25–40% of the total wet mass of a shell, including each integer and fraction within this specified range. In one non- limiting embodiment, the solvent may comprise a mass percentage of about 30–40%, or about 35–40%, of the total wet mass of a shell, including each integer and fraction within these specified ranges. Other suitable shell additives include plasticizers, opacifiers, colorants, humectants, preservatives, viscosity modifiers, flavorings, and buffering salts and acids. Further suitable shell additives may also include viscosity modifying polymers. Unlike viscosity modifiers, the viscosity modifying polymers act as viscosity reducing agent rather than a binding agent. The viscosity modifying polymers decrease the viscosity of the gel formulation while maintaining similar shell stability, and without affecting the shell rupture time and disintegration time. Opacifiers can be used to opacify the capsule shell when the encapsulated active agents are light sensitive. Suitable opacifiers include titanium dioxide, zinc oxide, calcium carbonate and combinations thereof. When included in softgel capsule compositions, as described herein, opacifiers typically comprise a mass percentage of about 0.01–1% of the total wet mass of a shell, including each fraction within this specified range. For example, one or more opacifiers may comprise a mass percentage of about 0.01%, 0.1%, 0.25%, 0.5%, 0.75%, 0.9%, or 1%, or about 0.01–0.1%, 0.01–0.25%, 0.01–0.5%, 0.01–0.75%, 0.01–0.9%, 0.1–0.25%, 0.1–0.5%, 0.1–0.75%, 0.1–0.9%, 0.1–1%, 0.25–0.5%, 0.25–0.75%, 0.25–0.9%, 0.25–1%, 0.5–0.75%, 0.5–0.9%, 0.5– 1%, 0.75–0.9%, 0.75–1%, or 0.9–1% of the total wet mass of a shell, including each fraction within these specified values and ranges. In some embodiments, one or more opacifiers may comprise a mass percentage of about 0.01–1% of the total wet mass of a shell, including each fraction within this specified range. Colorants can be used to for marketing and product identification / differentiation purposes. Suitable colorants include synthetic and natural dyes and combinations thereof. When included in softgel capsule compositions, as described herein, colorants typically comprise a mass percentage of about 0.01–10% of the total wet mass of a shell, including each integer and fraction within this specified range. For example, one or more colorants may comprise a mass percentage of about 0.01%, 0.1%, 0.25%, 0.5%, 1%, 2%, 2.5%, 5%, 7.5%, or 10%, or about 0.01–0.1%, 0.01–0.25%, 0.01–0.5%, 0.01–1%, 0.01–2%, 0.01–2.5%, 0.01–5%, 0.01–7.5%, 0.1–0.25%, 0.1– 0.5%, 0.1–1%, 0.1–2%, 0.1–2.5%, 0.1–5%, 0.1–7.5%, 0.1–10%, 0.25–0.5%, 0.25–1%, 0.25–2%, 0.25–2.5%, 0.25–5%, 0.25–7.5%, 0.25–10%, 0.5–1%, 0.5–2%, 0.5–2.5%, 0.5–5%, 0.5–7.5%, 0.5–10%, 1–2%, 1–2.5%, 1–5%, 1–7.5%, 1–10%, 2–2.5%, 2–5%, 2–7.5%, 2–10%, 2.5–5%, 2.5– 7.5%, 2.5–10%, 5–7.5%, 5–10%, or 7.5–10% of the total wet mass of a shell, including each integer and fraction within these specified values and ranges. In some embodiments, one or more colorants may comprise a mass percentage of about 0.01–10% of the total wet mass of a shell, including each integer and fraction within this specified range. Humectants can be used to suppress the water activity of the softgel. Suitable humectants include glycerin and sorbitol, which are often components of the plasticizer composition. Due to the low water activity of dried, properly stored softgel capsules, the greatest risk from microorganisms comes from molds and yeasts. For this reason, preservatives can be incorporated into the capsule shell. Suitable preservatives include alkyl esters of p-hydroxy benzoic acid such as methyl, ethyl, propyl, butyl and heptyl (collectively known as “parabens”), or combinations thereof. Flavorings or “flavorants” can be used to mask unpleasant odors and tastes of fill formulations. Suitable flavorings include synthetic and natural flavorings. The use of flavorings can be problematic due to the presence of aldehydes which can cross-link gelatin. As a result, buffering salts and acids can be used in conjunction with flavorings that contain aldehydes in order to inhibit cross-linking of the gelatin. When included in softgel capsule compositions, as described herein, flavorings typically comprise a mass percentage of about 0.01–1% of the total wet mass of a shell, including each fraction within this specified range. For example, one or more flavorings may comprise a mass percentage of about 0.01%, 0.1%, 0.25%, 0.5%, 0.75%, 0.9%, or 1%, or about 0.01–0.1%, 0.01–0.25%, 0.01–0.5%, 0.01–0.75%, 0.01–0.9%, 0.1–0.25%, 0.1– 0.5%, 0.1–0.75%, 0.1–0.9%, 0.1–1%, 0.25–0.5%, 0.25–0.75%, 0.25–0.9%, 0.25–1%, 0.5–0.75%, 0.5–0.9%, 0.5–1%, 0.75–0.9%, 0.75–1%, or 0.9–1% of the total wet mass of a shell, including each fraction within these specified values and ranges. In some embodiments, one or more flavorings may comprise a mass percentage of about 0.01–1% of the total wet mass of a shell, including each fraction within this specified range. Examples of suitable viscosity modifiers include guar gum, locust bean gum, xanthan gum, agar, and gellan gum. Fillers or bulking agents can be added to the shell composition if needed. Useful fillers or bulking agents are hydroxypropyl starch phosphate, acacia, alginic acid, microcrystalline cellulose, carboxymethylcellulose, hydroxypropyl methylcellulose, methylcellulose, ethylcellulose, pregelatinized starch, potato starch, tapioca starch, rice starch, corn starch, wheat starch, pea starch, modified starches, pregelatinized starch, microcrystalline cellulose, hydroxypropyl methylcellulose, lactose, dextrates, dextrin, dextrose, maltodextrin, glucose, sucrose, powdered sugar, sucrose syrup, mannitol, gums like xanthan gum, tragacantha, guar gum, acacia gum, arabic gum, ferula gummosa boiss, gum olibanum, beilschmiedia seed gum, aegle marmelos gum, okra gum, cassia roxburghii seeds gum, kaolin, talc, bentonite, calcium phosphates, calcium carbonate, magnesium carbonate, magnesium oxide, calcium sulphate, hydrogenated sodium chloride, potassium chloride, combinations or mixtures thereof, and others known in the art. Other useful fillers are N-Lok®, (starch sodium octenyl succinate), Hi-Cap™, and Ultra Sperse®M. Viscosity modifying polymers can be added to adjust the viscosity of the shell composition and change the formulations. The polymer may be added to the shell of the sofgel to change the gel viscosity, specifically reducing or decreasing the gel viscosity, thereby strengthening the gelatin ribbon and maintaining shell stability. These viscosity modifying polymers may be of low molecular weight. Viscosity modifying polymers may also be water soluble. Examples of viscosity modifying polymers may include but are not limited to HPMC, PVP, PVA, and Dextran. When included in softgel capsule compositions, the polymers typically comprise a mass percentage of about 1–20% of the total wet mass of a shell, including each fraction within this specified range. For example, one or more viscosity modifying polymers may comprise a mass percentage of about 1%, 5%, 10%, 15%, 20%, or ranging about 1–5%, 1-10%, 1–15%, 1–20%, 5–10%, 5–15%, 5–20% of the total wet mass of shell, including each fraction within these specified values and ranges. For example, about 1 to 20% of the total wet mass of low molecular weight PVP may be added to the shell, reducing its viscosity. The addition of the PVP at 5% (0.5), 10% (1), and 15% (1.5) is respectively shown in Table 20. With respect to Table 20, the average viscosity (CP) of compositions with PVP at 0%, PVP at 5%, and PVP at 15% are respectively 214,800, 71700, 11440 at T = 0 and 182,100, 41,040, 7,950 at T = 24 hrs. Disintegrations in water at 37 C (Gel Swatch Sample at 72 hrs) are respectively 16.37 min (0% PVP), 8.5 min (5% PVP), and 4.38 min (15% PVP). Further capsule rupture / disintegration tests were conducted for PVP at 5% and PVP at 10% with both MCT and PEG fills. The results (in minutes) are shown in Table 21 for both MCT and PEG with respect to the average capsule rupture and disintegration times. In some embodiments, the soft capsule shell composition comprises a top coating or a moisture barrier that is applied to the capsule shell. In one embodiment, the moisture barrier comprises one or more polyvinyl alcohols (PV) and appropriate pharmaceutically acceptable excipients. In one embodiment, the moisture barrier comprises polyvinyl alcohol, sodium lauryl sulfate, glyceryl mono-caprylate-caprate, and talc. In one aspect, the moisture barrier aids in preserving the cosmetic appearance of the dosage forms by preventing dimpling, sticking, or other processing or storage induced blemishes. The top coating may also comprise a sealant. In one aspect, the sealant can be a methacrylic acid copolymer, hydroxypropylmethylcellulose, or a proprietary sealant such as Kollicoat®Protect (BASF). Coatings, top coatings, or subcoatings are applied to the soft capsules using various methods known in the art. The coatings are typically prepared as suspensions and sprayed on capsules in perforated coating pans through one or more spray nozzles at a specific temperature. Coating solutions or dispersion may be applied at spray rates between 100 and 400 g / min. The spray rate may be proportionately higher for coatings with higher solid content and lower for more dilute dispersions. In one embodiment, capsules are coated using a pan coater. After the coating suspension is applied, the coated capsules are dried in the pan coater for a period of time at a specific temperature. In some embodiments, a softgel capsule as described herein may enrobe or encapsulate a pressed tablet comprising one or more active pharmaceutical ingredients for easier swallowing of the pressed tablet by a subject. As used herein, “enrobe” generally refers to coating a pressed tablet with a softgel capsule formulation to form an “enrobed tablet.” As used herein, “encapsulate” generally refers to coating a pressed tablet with a softgel capsule formulation to form an “encapsulated tablet,” where additional components or excipients may be present in the encapsulated tablet. In some embodiments, a softgel capsule as described herein may have one or more active pharmaceutical ingredients incorporated into the softgel capsule formulation in addition to or instead of in the matrix fill. In some embodiments, a rapid releasing softgel capsule as described herein may be utilized in chewable soft capsules containing solid, semisolid, gelatinous, or liquid fills, e.g., Chewels® or LiquiSoft® (Patheon Softgels Inc). See e.g., U.S. Pat. Nos. 8,097,279; 8,241,665; 8,765,174; 8,414,916; 9,072,677; 9,668,976; 9,861,586; 10,342,763; 9,867,779; and 10,555,901 each of which is incorporated by reference herein for such teachings. In some embodiments, rapid releasing softgel capsules may also be pre-stressed to enhance the release rate. Exemplary examples of pre-stressing including laser drilling, mechanical drilling, scoring, or other known means to pre-stress the gel capsule. Fill Compositions Fill compositions for the softgel capsules described herein can be aqueous or oil-based fills. Aqueous fills typically contain one or more polyethylene glycols, solubilizers, and other pharmaceutical excipients in addition to the API. Oil-based fills contain oils, waxes, surfactants, and other pharmaceutical excipients in addition to the API. Exemplary fill compositions are shown in Table 2. Table 2: Exemplary Rapid Release Capsule Fill Components Component Examples Mass Range (mg) Active Pharmaceutical Ingredients Any 0.1–2000 Nutraceuticals Agent Any 0.1–2000 Neutralizing Agents Any compatible 0.1–2000 Solvents Any compatible 0.1–2000 Co-solvents Any compatible 0.1–2000 Surfactants Any compatible 0.1–2000 Co-surfactants Any 0.1–2000 Theoretical Total Fill Weight 0.1–2000 mg In one embodiment, the fill contains one or more hydrophilic vehicles which may be anhydrous and compatible with soft gelatin capsules. Non-limiting exemplary vehicles comprise Capmul®MCM, Captex®355, Cremophor®RH 40, Croscarmellose, Crospovidone, Crospovidone CL, Crospovidone CL-F, Crospovidone CL-M, Imwitor®742, Kollidon®CL, Kollidon®CL-F, Kollidon®CL-M, Labrafac™ Lipophile WL 1349, Labrafil®M2125CS, Labrasol®, Lutrol®F 68, Maisine™ 35-1, mannitol, Miglyol®812, Pearlitol®Flash, Peceol®, Plurol®Oleique CC 497, Povidone K 17, Povidone K 30, polyethylene glycol 200, polyethylene glycol 400, polyethylene glycol 600, polyethylene glycol 800, polyethylene glycol 1000, polyethylene glycol 2000, polyethylene glycol 3350, propylene glycol, glycerol, Lycasin 80 / 55, sorbitol special, xylitol, maltitol or mixtures thereof. In one embodiment, the hydrophilic vehicle comprises one or more hydro-alcohols including polyethylene glycols of a molecular weight ranging from about 200 to about 8000, or a mixture or combination thereof. In another embodiment, the hydrophilic vehicle may comprise a hygroscopic polymer. In one embodiment, the hygroscopic polymers include polyvinylpyrrolidone, crospovidone, hydroxypropylmethylcellulose, hydroxypropylcellulose, ethyl cellulose, methylcellulose, and polyethylene oxide. Suitable hygroscopic polymers include polyvinyl alcohol, a copolymer of polyvinylpyrrolidone and polyvinyl acetate, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxymethyl cellulose, gelatin, polyethylene oxide, such as POLYOX™ 100,000–600,000 MW, acacia, dextrin, cyclodextrins, starch, poly hydroxyethylmethacrylate, a water-soluble non-ionic polymethacrylate or copolymer thereof, a modified cellulose, a modified polysaccharide, a non-ionic gum, or a non-ionic polysaccharide. In another embodiment, the fill may comprise one or more lipids or lipophilic vehicles. In one aspect, the lipid or lipophilic vehicle may be a liquid or a solid or a semisolid lipid or lipophilic vehicle. Suitable non-limiting liquid lipid or lipophilic vehicles comprise olive oil, soybean oil, sunflower oil, canola oil, palmitoleic acid, oleic acid, myristoleic acid, linoleic acid, arachidonic acid, paraffin oil, mineral oil, or a mixture or combination thereof. The lipid or lipophilic vehicle can be a semi-solid lipophilic vehicle such as a polyethylene glycol glyceride ester, e.g., Gelucire®33 / 01, Gelucire®37 / 02, Gelucire®39 / 01, Gelucire®43 / 01, Gelucire®44 / 14, Gelucire®50 / 02, Gelucire®50 / 13, Gelucire®53 / 10, or Gelucire®62 / 02; a paraffin wax, carnauba wax, or bee’s wax. In another embodiment, the fill may comprise release regulators such as fatty acid salts, fatty acid esters, or fatty acid polyoxyethylene derivatives. The release regulator can also be a surfactant having a hydrophilic / lipophilic balance (HLB) value between about 2 and about 40. The HLB characteristic of surfactants can be determined in accordance with “Physical Pharmacy: Physical Chemical Principles in the Pharmaceutical Sciences,” Fourth Edition, pp. 371-373, A. Martin, Ed., Lippincott Williams & Wilkins, Philadelphia (1993), which is incorporated by reference herein for such teachings. In another embodiment, the fill may comprise emulsifying or solubilizing agents such as acacia, cholesterol, diethanolamine, glyceryl monostearate, lanolin alcohols, lecithin, mono- and di-glycerides, monoethanolamines, oleic acids, oleyl alcohols, poloxamer, polyoxyethylene 50 stearate, polyoxyl 35 castor oil, polyoxyl 40 hydrogenated castor oil, polyoxyl 10 oleyl ether, polyoxyl 20 cetostearyl ether, polyoxyl 40 stearate, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, propylene glycol diacetate, propylene glycol monostearate, sodium lauryl sulfate, sodium stearate, sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate, sorbitan monostearate, stearic acid, simethicone, trolamine, emulsifying wax, or combinations thereof. Other suitable solvents include surfactants and copolymers of polyethylene glycols of a molecular weight ranging from about 200 to about 8000. Optionally, glycerin, PVP or propylene glycol (PPG) can be added to enhance the solubility of the drug agent. In another embodiment described herein, the matrix fill comprises one or more flavorings. In one embodiment, the one or more flavorings comprise citric acid, lactic acid, sodium citrate, anethole, benzaldehyde, ethyl vanillin, Eucalyptol, glycine, menthol, methyl salicylate, monosodium glutamate, orange flower oil, peppermint, peppermint oil, peppermint spirit, rose oil, stronger rose water, thymol, tolu balsam tincture, vanilla, vanilla tincture, vanillin, or combinations thereof. In one aspect, the flavorings comprise one or more of citric acid, acetic acid, lactic acid, malic acid, tartaric acid, or combinations thereof. In another aspect, the flavorings comprise citric acid, lactic acid, or combinations thereof. In another embodiment, the matrix fill comprises at least one or more sweeteners. In one embodiment, the one or more sweeteners comprise mannitol, thaumatin, glycyrrhizic acid salt, maltitol, sucralose, acesulfame salts, steviol glycosides (e.g., Stevia®, Truvía®), saccharin, calcium saccharin, sodium saccharin, aspartame, acesulfame potassium, agave nectar, high- fructose corn syrup, honey, dextrates, dextrose, excipient dextrose and simple sugars such as glucose, fructose, sucrose, sucralose, lactose, or combinations thereof. In one aspect, the sweeteners comprise one or more of mannitol, maltitol (e.g., Lycasin®), xylitol, sucralose, thaumatin (e.g., Talin®), glycyrrhizic acid salts (MagnaSweet®), or combinations thereof. In another embodiment, the matrix fill comprises at least one solvent. In one aspect, the solvent is water. The matrix fill can optionally include one or more pharmaceutically acceptable excipients. Examples of pharmaceutically acceptable excipients include buffers, such as phosphate buffers, citrate buffer, and buffers with other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers, such as polyvinyl pyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextrins; chelating agents, such as EDTA; sugar alcohols, such as mannitol or sorbitol; salt-forming counterions, such as sodium; and / or nonionic surfactants, such as TWEEN®(ICI, Inc.; Bridgewater, New Jersey), and PLURONICS™ (BASF; Florham Park, NJ). Diluents commonly used in the art can also be encapsulated within the shell, including water or other solvents, solubilizing agents, and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, 1,3-butylene glycol, dimethylformamide, oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, sesame oil, glycerol, tetrahydrofurfuryl alcohol, and fatty acid esters of sorbitan, and mixtures of these substances. Additional pharmaceutical excipients useful for matrix fills include, for example, the following: Acidifying agents (acetic acid, glacial acetic acid, citric acid, fumaric acid, hydrochloric acid, diluted hydrochloric acid, malic acid, nitric acid, phosphoric acid, diluted phosphoric acid, sulfuric acid, tartaric acid); Alkalizing agents (ammonia solution, ammonium carbonate, diethanolamine, diisopropanolamine, potassium hydroxide, sodium bicarbonate, sodium borate, sodium carbonate, sodium hydroxide, trolamine); Antifoaming agents (dimethicone, simethicone); Antimicrobial preservatives (benzalkonium chloride, benzalkonium chloride solution, benzethonium chloride, benzoic acid, benzyl alcohol, butylparaben, cetylpyridinium chloride, chlorobutanol, chlorocresol, cresol, dehydroacetic acid, ethylparaben, methylparaben, methylparaben sodium, phenol, phenylethyl alcohol, phenylmercuric acetate, phenylmercuric nitrate, potassium benzoate, potassium sorbate, propylparaben, propylparaben sodium, sodium benzoate, sodium dehydroacetate, sodium propionate, sorbic acid, thimerosal, thymol); Antioxidants (ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, hypophosphorous acid, monothioglycerol, propyl gallate, sodium formaldehyde sulfoxylate, sodium metabisulfite, sodium thiosulfate, sulfur dioxide, tocopherol, tocopherols excipient); Buffering agents (acetic acid, ammonium carbonate, ammonium phosphate, boric acid, citric acid, lactic acid, phosphoric acid, potassium citrate, potassium metaphosphate, potassium phosphate monobasic, sodium acetate, sodium citrate, sodium lactate solution, dibasic sodium phosphate, monobasic sodium phosphate); Chelating agents (edetate disodium, ethylenediaminetetraacetic acid and salts, edetic acid); Coating agents (sodium carboxymethylcellulose, cellulose acetate, cellulose acetate phthalate, ethylcellulose, gelatin, pharmaceutical glaze, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, methacrylic acid copolymer, methylcellulose, polyvinyl acetate phthalate, shellac, sucrose, titanium dioxide, carnauba wax, microcrystalline wax, zein); Colorants (caramel, red, yellow, black or blends, ferric oxide); Complexing agents (ethylenediaminetetraacetic acid and salts (EDTA), edetic acid, gentisic acid ethanolamide, oxyquinoline sulfate); Desiccants (calcium chloride, calcium sulfate, silicon dioxide); Emulsifying and / or solubilizing agents (acacia, cholesterol, diethanolamine (adjunct), glyceryl monostearate, lanolin alcohols, mono- and di-glycerides, monoethanolamine (adjunct), lecithin, oleic acid (adjunct), oleyl alcohol (stabilizer), poloxamer, polyoxyethylene 50 stearate, polyoxyl 35 castor oil, polyoxyl 40 hydrogenated castor oil, polyoxyl 10 oleyl ether, polyoxyl 20 cetostearyl ether, polyoxyl 40 stearate, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, diacetate, monostearate, sodium lauryl sulfate, sodium stearate, sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate, sorbitan monostearate, stearic acid, trolamine, emulsifying wax); Filtering aids (powdered cellulose, purified siliceous earth); Flavors and perfumes (anethole, benzaldehyde, ethyl vanillin, menthol, methyl salicylate, monosodium glutamate, orange flower oil, peppermint, peppermint oil, peppermint spirit, rose oil, stronger rose water, thymol, tolu balsam tincture, vanilla, vanilla tincture, vanillin); Humectants (glycerin, hexylene glycol, sorbitol); Plasticizers (e.g., castor oil, diacetylated monoglycerides, diethyl phthalate, glycerin, mono- and di-acetylated monoglycerides, propylene glycol, triacetin, triethyl citrate); Polymers (e.g., cellulose acetate, alkyl celluloses, hydroxyalkyl, acrylic polymers and copolymers); Solvents (acetone, alcohol, diluted alcohol, amylene hydrate, benzyl benzoate, butyl alcohol, carbon tetrachloride, chloroform, corn oil, cottonseed oil, ethyl acetate, glycerin, hexylene glycol, isopropyl alcohol, methyl alcohol, methylene chloride, methyl isobutyl ketone, mineral oil, peanut oil, propylene carbonate, sesame oil, water for injection, sterile water for injection, sterile water for irrigation, purified water); Sorbents (powdered cellulose, charcoal, purified siliceous earth); Carbon dioxide sorbents (barium hydroxide lime, soda lime); Stiffening agents (hydrogenated castor oil, cetostearyl alcohol, cetyl alcohol, cetyl esters wax, hard fat, paraffin, polyethylene excipient, stearyl alcohol, emulsifying wax, white wax, yellow wax); Suspending and / or viscosity-increasing agents (acacia, agar, alginic acid, aluminum monostearate, bentonite, purified bentonite, magma bentonite, carbomer, carboxymethylcellulose calcium, carboxymethylcellulose sodium, carboxymethylcellulose sodium, carrageenan, microcrystalline and carboxymethylcellulose sodium cellulose, dextrin, gelatin, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, magnesium aluminum silicate, methylcellulose, pectin, polyethylene oxide, polyvinyl alcohol, povidone, alginate, silicon dioxide, colloidal silicon dioxide, sodium alginate, tragacanth, xanthan gum); Sweetening agents (aspartame, dextrates, dextrose, excipient dextrose, fructose, mannitol, saccharin, calcium saccharin, sodium saccharin, sorbitol, solution sorbitol, sucrose, compressible sugar, confectioner’s sugar, syrup); Tablet binders (acacia, alginic acid, sodium carboxymethylcellulose, microcrystalline cellulose, dextrin, ethylcellulose, gelatin, liquid glucose, guar gum, hydroxypropyl methylcellulose, methylcellulose, polyethylene oxide, povidone, pregelatinized starch, syrup); Tablet and / or capsule diluents (calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulfate, microcrystalline cellulose, powdered cellulose, dextrates, dextrin, dextrose excipient, fructose, kaolin, lactose, mannitol, sorbitol, starch, pregelatinized starch, sucrose, compressible sugar, confectioner’s sugar); Tablet disintegrants (alginic acid, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, starch, pregelatinized starch); Tablet and / or capsule lubricants (calcium stearate, glyceryl behenate, magnesium stearate, light mineral oil, sodium stearyl fumarate, stearic acid, purified stearic acid, talc, hydrogenated vegetable oil, zinc stearate); Tonicity agent (dextrose, glycerin, mannitol, potassium chloride, sodium chloride); Vehicle: flavored and / or sweetened (aromatic elixir, compound benzaldehyde elixir, iso-alcoholic elixir, peppermint water, sorbitol solution, syrup, tolu balsam syrup); Vehicle: oleaginous (almond oil, corn oil, cottonseed oil, ethyl oleate, isopropyl myristate, isopropyl palmitate, mineral oil, light mineral oil, myristyl alcohol, octyldodecanol, olive oil, peanut oil, persic oil, sesame oil, soybean oil, squalane); Vehicle: solid carrier (sugar spheres); Vehicle: sterile (Bacteriostatic water for injection, bacteriostatic sodium chloride injection); Viscosity-increasing (see suspending agent); Water repelling agent (cyclomethicone, dimethicone, simethicone); and / or solubilizing agent (benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, docusate sodium, nonoxynol 9, nonoxynol 10, octoxynol 9, poloxamer, polyoxyl 35 castor oil, polyoxyl 40, hydrogenated castor oil, polyoxyl 50 stearate, polyoxyl 10 oleyl ether, polyoxyl 20, cetostearyl ether, polyoxyl 40 stearate, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, sodium lauryl sulfate, sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate, sorbitan monostearate, tyloxapol). This list is not meant to be exclusive, but instead merely representative of the classes of excipients and the particular excipients that may be used in the softgel dosage forms as described herein. In one embodiment, the matrix fill can include a release regulator such as a fatty acid salt, fatty acid ester, or fatty acid polyoxyethylene derivative. The release regulator can also be a surfactant having a hydrophilic / lipophilic balance (HLB) value between about 2 and about 40. The HLB characteristic of surfactants can be determined in accordance with Physical Pharmacy: Physical Chemical Principles in the Pharmaceutical Sciences, 4thed., 371-373, A. Martin, Ed., Lippincott Williams & Wilkins, Philadelphia (1993), which is incorporated by reference herein for such teachings. In one embodiment, the matrix fill may include one or more hydrophilic carriers. Examples of hydrophilic carriers are all natural, synthetic, or semi-synthetic products, which can be defined as aqueous carriers not mixable or only partially mixable with oil. All components can be used alone or if possible, in mixtures with different percentages. Among aqueous components which can be used as a dispersing phase or also as a dispersed phase. Examples of aqueous solutions of hydrophilic polymers, which are hydrosoluble or hydrodispersable of various nature, such as polyethylenglycol, polyvinyl pyrrolidone, polyacrylic acids and derivatives, such as Carbopol®971, polymethacrylic acids polyoxyethylenepolyoxypropylene copolymers (for example Poloxamer®, Lutrol™), hydrophilic polysaccharides of various nature, for example dextran, xanthan, scleroglucan, arabic gum, guar gum, chitosan, cellulose, or starch derivatives. In one embodiment, the matrix fill can include a neutralizing agent. In one aspect, the neutralizing agent comprises an organic acid, ester, or salt. In another aspect, the neutralizing agent comprises at least one of lactate, fumarate, caprylate, caprate, oleate, maleate, succinate, tartrate, citrate, glutamate, gluconate, esters or salts thereof, or combinations thereof. In one embodiment, the matrix fill can include a hydrophilic internal phase and a lipid or lipophilic external phase. The internal phase of the matrix fill can include a plasticizer, such as propylene glycol, or a solubility enhancing agent, such as polyethylene glycol of molecular mass ranging from about 200 g / mol to about 8000 g / mol. In another embodiment, the internal phase can include hydroalcoholic solutions of cellulose derivatives, hydrophilic polymers, polyacrylates, polyacrylic acids and derivatives (e.g., Carbopol™) polyvinyl polymers, chitosan, or combinations thereof. In another embodiment, the internal phase of the matrix fill can include polymers, such as methylcellulose, hydroxypropylmethylcellulose, polymethylmethacrylate, or polyvinylpyrrolidone (PVP). The internal phase of the matrix fill can also be structured. A “structured” internal phase of the matrix fill, as used herein, means a solid, semisolid, or a gel whose shape is relatively stable and does not usually aggregate to form a large globule. A structured internal phase of the matrix fill therefore provides controlled drug release and stabilizes the physical state of the matrix. Without being bound by any theory, it is believed that the structured nature of the matrix fill impedes solvation and / or diffusion of the active pharmaceutical ingredient out of the matrix fill. In another embodiment, the external phase of the matrix fill can include a vegetable oil, hydrogenated vegetable oil (including shortening), fatty acids, fatty acid esters, wax, bee’s wax, soybean oil, or a combination thereof. In another embodiment, an active pharmaceutical ingredient can be dispersed in the internal phase of the matrix fill as a suspension form. In one embodiment, the matrix fill is a liquid (e.g., a solution, suspension, or dispersion) or a semisolid (e.g., a paste or gel). In one aspect, the active pharmaceutical ingredient can be innately a liquid or semisolid. In another aspect, the active ingredient can be prepared as a liquid or semisolid by, for example, by dissolving or otherwise mixing an active ingredient and optionally one or more pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, glycols (e.g., propylene glycol), ethanol, fatty acids, glycerides, oils, sterols, phospholipids, and the like, to thereby form a solution. In one embodiment described herein, the matrix fill comprises a lipid or lipophilic vehicle that provides a suspension of an active pharmaceutical ingredient having defined sizes. In one aspect, a soft capsule comprising a suspension of an active pharmaceutical ingredient provides rapid release delivery of the active pharmaceutical ingredient. In one embodiment described herein, the pharmaceutical composition provides matrix fills for an active pharmaceutical ingredient, or derivatives thereof, based on lipids or lipophilic materials. The described matrices have a hydrophobic (lipophilic) surface in contact with a hydrophilic soft capsule shell to minimize any potential shell-fill interactions, such as when the soft capsules are filled with hydrophilic materials. APIs Examples of active pharmaceutical ingredients that can be included comprise agents classified as, for example, an adrenocortical steroid, adrenocortical suppressant, aldosterone antagonist, amino acid, anabolic steroid, androgen, antagonist, anthelmintic, anti-acne agent, anti-adrenergic, anti-allergic, anti-amebic, anti-androgen, anti-anemic, anti-anginal, anti-arthritic, anti-asthmatic, anti-atherosclerotic, antibacterial, anticholelithic, anticholelithogenic, anticholinergic, anticoagulant, anticoccidal, antidiabetic, antidiarrheal, antidiuretic, antidote, anti- estrogen, antifibrinolytic, antifungal, antiglaucoma agent, antihemophilic, antihemorrhagic, antihistamine, antihyperlipidemic, antihyperlipoproteinemic, antihypertensive, antihypotensive, anti-infective, anti-infective, anti-inflammatory, antikeratinizing agent, antimalarial, antimicrobial, antimitotic, antimycotic, antineoplastic, antineutropenic, antiparasitic, antiperistaltic, antipneumocystic, antiproliferative, antiprostatic hypertrophy, antiprotozoal, antipruritic, antipsoriatic, antirheumatic, antischistosomal, antiseborrheic, antisecretory, antispasmodic, antithrombotic, antitussive, anti-ulcerative, anti-urolithic, antiviral, appetite suppressant, benign prostatic hyperplasia therapy agent, bone resorption inhibitor, bronchodilator, carbonic anhydrase inhibitor, cardiac depressant, cardioprotectant, cardiotonic, cardiovascular agent, choleretic, cholinergic, cholinergic agonist, cholinesterase deactivator, coccidiostat, contrasting agent, diagnostic aid, diuretic, ectoparasiticide, enzyme inhibitor, estrogen, fibrinolytic, free oxygen radical scavenger, glucocorticoid, gonad-stimulating principle, hair growth stimulant, hemostatic, hormone, hypocholesterolemic, hypoglycemic, hypolipidemic, hypotensive, imaging agent, immunizing agent, immunomodulator, immunoregulator, immunostimulant, immunosuppressant, impotence therapy adjunct, inhibitor, keratolytic, LHRH agonist, liver disorder treatment, luteolysin, mucolytic, mydriatic, nasal decongestant, neuromuscular blocking agent, non- hormonal sterol derivative, nonsteroidal anti-inflammatory drugs, oxytocic, plasminogen activator, platelet activating factor antagonist, platelet aggregation inhibitor, potentiator, progestin, prostaglandin, prostate growth inhibitor, prothyrotropin, radioactive agent, regulator, relaxant, repartitioning agent, scabicide, sclerosing agent, selective adenosine A1 antagonist, steroid, suppressant, symptomatic multiple sclerosis, synergist, thyroid hormone, thyroid inhibitor, thyromimetic, amyotrophic lateral sclerosis agents, Paget’s disease agents, unstable angina agents, uricosuric, vasoconstrictor, vasodilator, vulnerary, wound healing agent, and xanthine oxidase inhibitor. Further examples of suitable pharmaceutical ingredients include those as listed in the Merck Index (13thEdition, Wiley, 2001), The United States Pharmacopeia–National Formulary (USP–NF), and the FDA’s Orange book, which are each incorporated by reference herein for their teachings of pharmaceutically active ingredients. The formulation can contain any therapeutic, diagnostic, prophylactic or nutraceutical agent. Exemplary agents include, but are not limited to, analeptic agents; analgesic agents; anesthetic agents; antiasthmatic agents; antiarthritic agents; anticancer agents; anticholinergic agents; anticonvulsant agents; antidepressant agents; antidiabetic agents; antidiarrheal agents; antiemetic agents; antihelminthic agents; antihistamines; antihyperlipidemic agents; antihypertensive agents; anti-infective agents; anti-inflammatory agents; antimigraine agents; antineoplastic agents; antiparkinson drugs; antipruritic agents; antipsychotic agents; antipyretic agents; antispasmodic agents; antitubercular agents; antiulcer agents; antiviral agents; anxiolytic agents; appetite suppressants (anorexic agents); attention deficit disorder and attention deficit hyperactivity disorder drugs; cardiovascular agents including calcium channel blockers, antianginal agents, central nervous system (“CNS”) agents, beta-blockers and antiarrhythmic agents; central nervous system stimulants; diuretics; genetic materials; hormonolytics; hypnotics; hypoglycemic agents; immunosuppressive agents; muscle relaxants; narcotic antagonists; nicotine; nutritional agents; parasympatholytics; peptide drugs; psychostimulants; sedatives; sialagogues, steroids; smoking cessation agents; sympathomimetics; tranquilizers; vasodilators; beta-agonist; and tocolytic agents. A first class of drugs is selected based on inclusion in the molecule of a weakly acidic, basic, or amphoteric group that can form a salt. Any drug that bears an acidic or a basic functional group, for example, an amine, imine, imidazoyl, guanidine, piperidinyl, pyridinyl, quaternary ammonium, or other basic group, or a carboxylic, phosphoric, phenolic, sulfuric, sulfonic, or other acidic group, can react with the de-ionizing agent. Some specific drugs that bear acidic or basic functional groups and thus may be converted to the corresponding salt for use in the described formulations include, but are not limited to, acetaminophen, acetylsalicylic acid, alendronic acid, alosetron, amantadine, amlodipine, anagrelide, argatroban, atomoxetine, atorvastatin, azithromycin dehydrate, balsalazide, bromocriptin, bupropion, candesartan, carboplatin, ceftriaxone, clavulanic acid, clindamycin, cimetadine, dehydrocholic (acid), dexmethylphenidate, diclofenac, dicyclomine, diflunisal, diltiazem, donepezil, doxorubicin, doxepin, epirubicin, etodolic acid, ethacrynic acid, fenoprofen, fluoxetine, flurbiprofen, furosemide, gemfibrozil, hydroxyzine, ibuprofen, imipramine, indomethacin, ketoprofen, levothyroxine, maprotiline, meclizine, methadone, methylphenidate, minocycline, mitoxantrone, moxifloxacin, mycophenolic acid, naproxen, niflumic acid, ofloxacin, ondansetron, pantoprazole, paroxetine, pergolide, pramipexole, phenytoin, pravastatin, probenecid, rabeprazole, risedronic acid, retinoic acid, ropinirole, selegiline, sulindac, tamsulosin, telmisartan, terbinafine, theophyline, tiludronic acid, tinzaparin, ticarcillin, tomentin, valproic acid, salicylic acid, sevelamer, ziprasidone, zoledronic acid, acetophenazine, albuterol, almotriptan, amitriptyline, amphetamine, atracurium, beclomethasone, benztropine, biperiden, bosentan, bromodiphenhydramine, brompheniramine carbinoxamine, caffeine, capecitabine, cabergoline, cetirizine, chlocylizine, chlorpheniramine, chlorphenoxamine, chlorpromazine, citalopram, clavulanate potassium, ciprofloxacin, clemastine, clomiphene, clonidine, clopidogrel, codeine, cyclizine, cyclobenzaprine, cyproheptadine, delavirdine, diethylpropion, divalproex, desipramine, dexmethylphenidate, dexbrompheniramine, dexchlopheniramine, dexchlor, dextroamphetamine, dexedrine, dextromethorphan, fiflunisal, diphemanil methylsulphate, diphenhydramine, dolasetron, doxylamine, enoxaparin, ergotamine, ertepenem, eprosartan, escitalopram, esomeprazole, fenoldopam, fentanyl, fexofenadine, flufenamic acid, fluvastatin, fluphenazine, fluticasone, fosinopril, frovatriptan, gabapentin, galatamine, gatifloxacin, gemcitabine, haloperidol, hyalurondate, hydrocodone, hydroxychloroquine, hyoscyamine, imatinib, imipenem, ipatropin, lisinopril, leuprolide, levopropoxyphene, losartan, meclofenamic acid, mefanamic acid, mesalamine, mepenzolate, meperidine, mephentermine, mesalimine, mesoridazine, metaproteranol, metformin, methdialazine, methscopolamine, methysergide, metoprolol, metronidazole, mibefradil, montelukast, morphine, mometasone, naratriptan, nelfinavir, nortriptylene, noscapine, nylindrin, omeprazole, orphenadrine, oseltamivir, oxybutynin, papaverine, pentazocine, phendimetrazine, phentermine, pioglitazone, pilocarpine, prochloroperazine, pyrilamine, quetapine, ranitidine, rivastigmine, rosiglitazone, salmetrol, sertaline, sotalol, sumatriptan, tazobactam, tacrolimus, tamoxifen, ticlopidine, topiramate, tolterodine, triptorelin, triplennamine, triprolidine, tramadol, trovofloxacin, ursodiol, promazine, propoxyphene, propanolol, pseudoephedrine, pyrilamine, quinidine, oxybate sodium, sermorelin, tacrolimus, tegaseroid, teriparatide, tolterodine, triptorelin pamoate, scoplolamine, venlafaxine, zamivir, aminocaproic acid, aminosalicylic acid, hydromorphone, isosuprine, levorphanol, melhalan, nalidixic acid, and para-aminosalicylic acid. In one embodiment, the compositions described herein comprise one or more active pharmaceutical ingredients useful for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of pain, inflammation, fever, or symptoms stemming from cough or cold. In one embodiment described herein, the active pharmaceutical ingredient comprises one or more of astemizole, azelastine, azatadine, brompheniramine, carbinoxamine, cetirizine, chlorpheniramine, clemastine, cyproheptadine, desloratadine, dexbrompheniramine, dexchlorpheniramine, diphenhydramine, fexofenadine, hydroxyzine, levocetirizine, loratadine, phenindamine, pheniramine, phenyltoloxamine, promethazine, pyrilamine, terfenadine, tripelennamine, triprolidine, acetyl dihydrocodeine, benproperine, benzonatate, benzylmorphine, bibenzonium bromide, butamirate, butorphanol, carbetapentane, chlophedianol, clobutinol, clofedanol, cloperastine, codeine, dextromethorphan, diacetylmorphine, dibunate, dihydrocodeine, dimemorfan, dimethoxanate, diphenhydramine, dropropizine, droxypropine, ethylmorphine, fedrilate, glaucine, hydrocodone, hydromorphone, isoaminile, laudanum, levodropropizine, levomethadone, levopropoxyphene, meprotixol, methadone, morclofone, nepinalone, nicocodine, nicodicodine, normethadone, noscapine, oxeladin, oxolamine, pentoxyverine, pholcodine, pipazetate, piperidione, prenoxdiazine, tipepidine, zipeprol, acetylcysteine, althea root, ambroxol, antimony pentasulfide, bromhexine, carbocisteine, cineole, combinations, combinations, creosote, dembrexine hydrochloride, domiodol, dornase alfa, eprazinone, erdosteine, guaiacolsulfonate, guaifenesin, hederae helicis folium, ipecacuanha, letosteine, levo verbenone, mannitol, mesna, neltenexine, potassium iodide, senega, sobrerol, stepronin, tiopronin, tyloxapol, or combinations thereof. In one aspect, the active pharmaceutical ingredient comprises one or more of dextromethorphan hydrobromide, menthol, or combinations thereof. In one embodiment described herein, the active pharmaceutical ingredient is an anti- allergy agent. Exemplary anti-allergy agents include pseudoephedrine, cetirizine, loratadine, fexofenadine, diphenhydramine, levocetirizine, desloratadine, or combinations thereof. In one embodiment described herein, the active pharmaceutical ingredient is an oral rinsing agent. Exemplary oral rinsing agents include phenol, ethanol, thymol, eucalyptol, ethanol, methyl salicylate, chlorhexidine gluconate, cetylpyridinium chloride, hexetidine, triclosan, hydrogen peroxide, domiphen bromide, or combinations thereof. In one embodiment described herein, the active pharmaceutical ingredient comprises an oral rinsing agent comprising one or more of ethanol (about 20% to about 30%) menthol (0.042%), thymol (0.064%), methyl salicylate (0.06%), and eucalyptol (0.092%). In one embodiment described herein, the active pharmaceutical ingredient is an antidiarrheal or antacid comprising bismuth subsalicylate, loperamide hydrochloride, aluminum hydroxide, magnesium hydroxide, simethicone, aluminum carbonate, calcium carbonate, sodium bicarbonate, magnesium aluminum silicate, hydrotalcite, magaldrate, cimetidine, famotidine, nizatidine, ranitidine, lansoprazole, omeprazole, esomeprazole, rabeprazole, pantoprazole, dexlansoprazole, or combinations thereof. In one embodiment described herein, the active pharmaceutical ingredient comprises one or more of bismuth subsalicylate (~17.6 mg), benzoic acid, D&C Red No. 22, D&C Red No. 28, flavoring, magnesium aluminum silicate, methylcellulose, sodium saccharin, salicylic acid, sodium salicylate, sorbic acid, and water. In another embodiment, the active pharmaceutical ingredient is an irritable bowel syndrome therapeutic. Exemplary non-limiting active pharmaceutical ingredients useful for the treatment of irritable bowel syndrome comprise antidiarrheals such as atropine, diphenoxylate (Lomotil®), dicyclomine (Bentyl®), loperamide (Imodium®), rifaximin (Xifaxan®), alosetron (Lotronex®); bile acid binding agents such as cholestyramine (Prevailite®); constipation therapeutics such as linaclotide (Linzess®) or lubiprostone (Amitiza) or combinations thereof. In one embodiment described herein, the active pharmaceutical ingredient is a constipation therapeutic such as linaclotide (Linzess®) or lubiprostone (Amitiza®), methylcellulose, polycarbophil, psyllium, mineral oil, glycerol, docusate sodium, sodium bicarbonate, sodium phosphate, magnesium citrate, magnesium oxide, magnesium sulfate, bisacodyl, sennosides, senna, castor oil or combinations thereof. In another embodiment described herein, the active pharmaceutical ingredient comprises one or more corticosteroids for treating inflammatory diseases and conditions and inflammation of the gastrointestinal tract, including but not limited to esophageal inflammation. In one embodiment described herein, the active pharmaceutical ingredient comprises one or more corticosteroids including but not limited to alclometasone, amcinonide, beclometasone, betamethasone, budesonide, ciclesonide, clobetasol, clobetasone, clocortolone, cloprednol, cortivazol, deflazacort, deoxycorticosterone, desonide desoximetasone, dexamethasone, diflorasone, diflucortolone, difluprednate, fluclorolone, fludrocortisone, fludroxycortide, flumetasone, flunisolide, fluocinolone acetonide, fluocinonide, fluocortin, fluocortolone, fluorometholone, fluperolone, fluticasone, fluticasone propionate, fluprednidene, formocortal, halcinonide, halometasone, hydrocortisone aceponate, hydrocortisone buteprate, hydrocortisone butyrate, loteprednol, medrysone, meprednisone, methylprednisolone, methylprednisolone aceponate, mometasone furoate, paramethasone, prednicarbate, prednisone, prednisolone, prednylidene, rimexolone, tixocortol, triamcinolone, ulobetasol, combinations thereof, or pharmaceutically acceptable salts, or esters thereof. In another embodiment described herein, the active pharmaceutical ingredient comprises one or more of 5-fluorouracil, 5-fluorodeoxyuridine, capecitabine, derivatives thereof, or combinations thereof for treating neoplasia, including but not limited to head and neck neoplasia. In another embodiment described herein, the active pharmaceutical ingredient comprises one or more of calcium supplements or calcimimetics including but not limited to cinacalcet, derivatives thereof, or combinations thereof for treating hyperthyroidism, hypercalcemia, hyperparathyroidism, parathyroid carcinoma, or a combination thereof. In some embodiments, the active pharmaceutical ingredient is a sleep aid. Examples of sleep aids include, but are not limited to doxylamine, diphenhydramine hydrochloride, melatonin, l-theanine, or combinations thereof. In some embodiments, the active pharmaceutical ingredient is an oral saliva substitute, such as, for example: monofluorophosphate, lactoferrin, lysozyme, lactoperoxidase, glucose oxidase, mutanase, dextranase, glycerol, or combinations thereof. In some embodiments, the active pharmaceutical ingredient is a teeth-bleaching or teeth- whitening agent, including but not limited to carbamide peroxide, sodium bicarbonate, hydrated silica, silicon dioxide, polyvinylpyrrolidone, potassium nitrate, sodium monofluorophosphate, sodium tripolyphosphate, strontium chloride, or combinations thereof. In another embodiment, the active pharmaceutical ingredient is a tooth enamel-enhancing agent. Exemplary tooth enamel enhancing agents include potassium nitrate, strontium acetate, strontium chloride, calcium sodium phosphosilicate, or combinations thereof. In another embodiment, the active pharmaceutical ingredient is an oral anesthetic, including but not limited to benzocaine, lidocaine, clove oil, or combinations thereof. In one embodiment, the active pharmaceutical ingredient is an effervescent including but not limited to sodium bicarbonate, citric acid, tartaric acid, or combinations thereof. Effervescent may be combined with one or more cold, cough, allergy, nasal decongestant, antitussive, expectorant, antihistamine, stimulant, sedative, anti-inflammatory, antibiotic, anti-viral, anti- asthmatic, anti-migraine, hypnotic, narcotic analgesic, or narcotic antagonist active pharmaceutical ingredients, or further combinations thereof. In one embodiment described herein, the active pharmaceutical ingredient is one or more non-steroidal anti-inflammatory drugs (NSAID). Non-limiting examples of NSAID active pharmaceutical ingredients comprise aspirin, ibuprofen, aceclofenac, acemetacin, aloxiprin, azapropazone, benorilate, bromfenac, carprofen, celecoxib, choline magnesium salicylate, diclofenac, diflunisal, etodolac, etoricoxib, faislamine, fenbufen, fenoprofen, flurbiprofen, indometacin, ketoprofen, ketorolac, lornoxicam, loxoprofen, meloxicam, meclofenamic acid, mefenamic acid, meloxicam, metamizole, methyl salicylate, magnesium salicylate, nabumetone, naproxen, nimesulide, oxyphenbutazone, paracetamol, parecoxib, phenylbutazone, piroxicam, salicyl salicylate, sulindac, sulfinpyrazone, suprofen, tenoxicam, tiaprofenic acid, tolmetin, valdecoxib, or combinations thereof. In another embodiment, suitable active pharmaceutical ingredients can comprise analgesics, such as, for example: acetylsalicylic acid, aloxiprin, aminophenazone, anilides, benorilate, benzomorphan derivatives, bezitramide, bucetin, buprenorphine, butorphanol, carbasalate calcium, choline salicylate, codeine, dextromoramide, dextropropoxyphene, dezocine, diamorphine, diflunisal, dihydrocodeine, dihydrocodone, dihydromorphine, diphenylpropylamine derivatives, dipyrocetyl, ethenzamide, fentanyl, floctafenine, flupirtine, glafenine, guacetisal, hydrocodone, hydrocodone bitartrate, hydromorphone, hydromorphone hydrochloride, imidazole salicylate, ketobemidone, metamizole sodium, methadone, morphinan derivatives, morphine, morphine sulphate pentahydrate, morphine-6-glucuronode, morpholine salicylate, nalbuphine, natural opium alkaloids, nefopam, nicomorphine, nifenazone, norhydrocodone, noroxycodone, opioids, opium, oripavine derivatives, oxycodeine, oxycodone, oxycodone hydrochloride, oxymorphone, papaveretum, pentazocine, pethidine, phenacetin, phenazocine, phenazone, phenylpiperidine derivatives, piritramide, potassium salicylate, propacetamol, propyphenazone, pyrazolones, rimazolium, salicylamide, salicylic acid derivatives, salsalate, sodium salicylate, tapentadol, tilidine, tramadol, viminol, ziconotide, or combinations thereof. In another embodiment, the active pharmaceutical ingredient disclosed herein includes an opioid, the opioid is selected from buprenorphine, codeine, dextromoramide, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, morphine, pentazocine, oxycodeine, oxycodone, oxymorphone, norhydrocodone, noroxycodone, morphine-6-glucuronode, tramadol, tapentadol, dihydromorphine, or combinations thereof. In one embodiment described herein, the active pharmaceutical ingredient is a probiotic. Exemplary probiotics include Bifidobacterium infantis 35624, Bifidobacterium lactis HN019, Lactobacillus reuteri ATCC55730, Lactobacillus rhamnosus, Lactobacillus casei DN-114 001, Bifidobacterium lactis Bb-12 or combinations thereof. In another embodiment, the active pharmaceutical ingredient comprises active drug substances used in the treatment of addictive disorders, such as, for example: nicotine, nicotine polacrilex, bupropion, varenicline, disulfiram, calcium carbimide, acamprosate, naltrexone, buprenorphine, methadone, levacetylmethadol, lofexidine, betahistine, cinnarizine, flunarizine, acetylleucine, gangliosides, ganglioside derivatives, tirilazad, riluzole, xaliproden, hydroxybutyric acid, amifampridine, or combinations thereof. In one embodiment described herein, the active pharmaceutical ingredient comprises one or more of nicotine (~2 mg), acesulfame potassium, magnesium oxide, menthol, peppermint oil, xylitol, sodium bicarbonate, sodium carbonate, or combinations thereof. In another embodiment, the active pharmaceutical ingredient can comprise those found in energy drinks, including caffeine, taurine, ginko biloba, glucuronolactone, inositol, niacin, niacinamide, D-pantothenol, panax ginseng root extract, pyridoxine HCl, vitamin B12, cyanocobalamin, riboflavin, guarana, L-carnitine, or combinations thereof. In another embodiment, the pharmaceutical composition can comprise vitamins or minerals. “Vitamins” as used herein refer to nutraceuticals or pharmaceutical ingredients comprising organic substances that are typically considered essential for the normal growth and activity of a subject (e.g., a human or non-human animal patient to whom the composition is to be administered). Non-limiting examples of vitamins include, but are not limited to, vitamin A (retinol), B1 (thiamine), B2 (riboflavin), B complex, B6 (pyridoxine), B12 (cobalamin), C (ascorbic acid), D (cholecalciferol), E (tocopherol), F (linoleic acid), G, H (biotin), and K, and choline, folic acid, inositol, niacin, pantothenic acid, para-aminobenzoic acid or combinations thereof. Vitamins can also include naturally occurring inorganic substances (e.g., minerals) that are typically considered essential for the normal growth and activity of a subject (e.g., a human or non-human animal patient to whom the composition is to be administered). Examples of minerals include, but are not limited to, boron, calcium, chromium, copper, iron, magnesium, manganese, molybdenum, nickel, phosphorus, selenium, silicon, tin, vanadium, or zinc. In some embodiments, the active pharmaceutical ingredient is a pharmaceutical a nutraceutical. Examples of nutraceuticals include, but are not limited to, amino acids, terpenoids (e.g., carotenoid terpenoids and non-carotenoid terpenoids), herbal supplements, homeopathic supplements, glandular supplements, polyphenolics, flavonoid polyphenolics, phenolic acids, curcumin, resveratrol, lignans, glucosinolates, isothiocyanates, indoles, thiosulfinates, phytosterols, anthraquinones, capsaicin, piperine, chlorophyll, betaine, oxalic acid, acetyl-L- carnitine, allantoin, androstenediol, androstendione, betaine (trimethylglycine), caffeine, calcium pyruvate (pyruvic acid), carnitine, carnosine, carotene, carotenoid, choline, chlorogenic acid, cholic acid, chondroitin sulfate, chondroitin sulfate, cholestan, chrysin, coenzyme Q10, conjugated linoleic acid, corosolic acid, creatine, dehydroepiandrosterone, dichlorophen, diindolymethane, dimethylglycine, dimercapto succinic acid, ebselen, ellagic acid, enzymes, fisetin, formononetin, glucaric acid (glucarate), glucosamine (HCl or sulfate), glucosamine (N- acetyl), glutathione, hesperidine, hydroxy-3-methylbutyric acid, 5-hydroxytryptophan, indole-3- carbinol, inositol, isothiocyanates, linolenic acid-gamma, lipoic acid (alpha), melatonin, methylsulfonylmethane, minerals, naringin, pancreatin, para-aminobenzoic acid, paraben (methyl or propyl), phenolics, phosphatidylcholine, phosphatidylserine, phospholipids, phytosterols, progesterone, pregnenolone, omega-3 fatty acids, quercetin, resveratrol, D-ribose, rutin, S- adenosylmethionine, salicylic acid, sulforaphane, tartaric acid, taxifolin, tetrahydropalmatine, theophyline, theobromine, tigogenin, troxerutin, tryptophan, tocotrienol (alpha, beta, and gamma), zeaxanthin, gingko biloba, ginger, cat’s claw, hypericum, aloe vera, evening primrose, garlic, ginseng, capsicum, dong quai, ginseng, feverfew, fenugreek, echinacea, green tea, marshmallow, saw palmetto, tea tree oil, fish oil, psyllium, kava-kava, licorice root, mahonia aquifolium, hawthorne, tumeric, witch hazel, yohimbe, aleurain, mistletoe, bilberry, bee pollen, peppermint oil, beta-carotene, genistein, lutein, lycopene, polyphenols, and the like. Further examples of suitable nutraceuticals include those listed in Handbook of Nutraceuticals and Functional Foods, Robert E. C. Wildman, Ed., CRC Press (2001), which is incorporated by reference herein for the teachings related to nutraceuticals. Other useful pharmaceutical ingredients or nutraceuticals that can be included as an active ingredient include fish oils, egg oils, squid oils, krill oils, nut oils, seed oils; soy oils, avocado oils, seabuckthorn seed or berry oils, clary sage seed oils, algal oils, flaxseed oils, sacha ichi oils, echium oils, hemp oils, omega-3 fatty acids, polyunsaturated omega-3 fatty acids, hexadecatrienoic acid (HTA), alpha-linolenic acid (ALA), stearidonic acid (SDA), eicosatrienoic acid (ETE), eicosatetraenoic acid (ETA), eicosapentaenoic acid (EPA, timnodonic acid), heneicosapentaenoic acid (HPA), docosapentaenoic acid (DPA), clupanodonic acid), docosahexaenoic acid (DHA, cervonic acid), tetracosapentaenoic acid, tetracosahexaenoic acid (nisinic acid), and free acids, etheyl esters, or other esters or salts thereof. In one aspect, the pharmaceutical ingredient is a highly purified omega-3 fatty acid, ester, or salt thereof. In one embodiment described herein, an active pharmaceutical ingredient is the only active ingredient in the pharmaceutical composition. In another embodiment, the active ingredient or drug can be an active pharmaceutical ingredient, derivatives thereof, or combinations thereof. In one embodiment, the pharmaceutical compositions as described herein are suitable for use for water soluble as well as slightly soluble or insoluble active drug substances. In another embodiment, the pharmaceutical compositions described herein may comprise pharmaceutically acceptable salts of any of the above-mentioned active drug substances. The term “pharmaceutically acceptable salts” of an active pharmaceutical ingredient includes alkali metal salts such as, for example, sodium or potassium salts, alkaline earth metal salts such as, for example, calcium and magnesium salts, and salts with organic or inorganic acid such as, for example, hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, maleic acid, succinic acid, tartaric acid, methanesulphonic acid, toluenesulphonic acid etc. In another embodiment, the active pharmaceutical ingredient may also be in the form of pharmaceutically acceptable salts, uncharged or charged molecules, molecular complexes, solvates, or anhydrates thereof, and, if relevant, single isomers, enantiomers, racemic mixtures, or mixtures thereof. In another embodiment, the active pharmaceutical ingredient may be in any of its crystalline, polymorphous, semi-crystalline, amorphous, or polyamorphous forms or mixtures thereof. In one embodiment described herein, the ratio of the active ingredient or drug to the total matrix fill, e.g., matrix fill ingredient(s) and active pharmaceutical ingredient(s), can be from about 1:50 to about 1:1 by weight, including all ratios in the specified range. In another embodiment described herein, the active ingredient to total matrix fill ratio can also be from about 1:16 to about 1:1 by weight, including all ratios in the specified range. The active ingredient to total matrix fill ratio can also be about 1:16; about 1:9; about 1:3; about 1:2; or about 1:1 including all ratios in the specified range. In one embodiment described herein, the active ingredient or drug comprises from about 5% to about 80% of the matrix fill mass including all iterations of integers within the specified range. In one aspect described herein, the active ingredient or drug comprises about 80% of the matrix fill mass. In another aspect, the active ingredient or drug comprises about 60% of the matrix fill mass. In another aspect, the active ingredient or drug comprises about 40% of the matrix fill mass. In another aspect, the active ingredient or drug comprises about 6% of the matrix fill mass. In another embodiment described herein, the active ingredient or drug comprises about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 15%, about 10%, about 5%, about 2%, or about 1% of the matrix fill mass. In one embodiment described herein, the weight ratio range of the active pharmaceutical ingredient to the matrix fill mass is about 1:20 to about 10:1. In one aspect, the weight ratio of the active pharmaceutical ingredient to the matrix fill mass is about 1:3. In another aspect, the weight ratio of the active pharmaceutical ingredient to the matrix fill mass is about 1:9. In another aspect, the weight ratio of the active pharmaceutical ingredient to the matrix fill mass is about 1:17. In some embodiments, one or more active pharmaceutical ingredients may be incorporated into a softgel capsule as described herein. In one embodiment, the composition described herein can provide a dosage of an active ingredient for administration. The dosage form can be administered, for example, to a subject, or a subject in need thereof. In one aspect, the subject may be a mammal, or a mammal in need thereof. In another aspect, the dosage form can be administered, for example, to a human or a human in need thereof. In another aspect, the human subject or a human subject in need thereof is a medical patient. In one embodiment, the pharmaceutical composition described herein, comprises an active pharmaceutical ingredient of about 0.01 mg to about 2000 mg, including all integers within the specified range. In one aspect, the active pharmaceutical ingredient is about 0.01 mg, 0.05 mg, 0.1 mg, 0.5 mg, 1 mg, 2 mg, 5 mg, 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, about 710 mg, about 720 mg, about 730 mg, about 740 mg, about 750 mg, about 760 mg, about 770 mg, about 780 mg, about 790 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 980 mg, about 990 mg, about 1000 mg, about 1010 mg, about 1020 mg, about 1030 mg, about 1040 mg, about 1050 mg, about 1060 mg, about 1070 mg, about 1080 mg, about 1090 mg, about 1100 mg, about 1110 mg, about 1120 mg, about 1130 mg, about 1140 mg, about 1150 mg, about 1160 mg, about 1170 mg, about 1180 mg, about 1190 mg, about 1200 mg, about 1210 mg, about 1220 mg, about 1230 mg, about 1240 mg, about 1250 mg, about 1260 mg, about 1270 mg, about 1280 mg, about 1290 mg, about 1300 mg, about 1310 mg, about 1320 mg, about 1330 mg, about 1340 mg, about 1350 mg, about 1360 mg, about 1370 mg, about 1380 mg, about 1390 mg, about 1400 mg, about 1410 mg, about 1420 mg, about 1430 mg, about 1440 mg, about 1450 mg, about 1460 mg, about 1470 mg, about 1480 mg, about 1490 mg, about 1500 mg, about 1510 mg, about 1520 mg, about 1530 mg, about 1540 mg, about 1550 mg, about 1560 mg, about 1570 mg, about 1580 mg, about 1590 mg, about 1600 mg, about 1610 mg, about 1620 mg, about 1630 mg, about 1640 mg, about 1650 mg, about 1660 mg, about 1670 mg, about 1680 mg, about 1690 mg, about 1700 mg, about 1710 mg, about 1720 mg, about 1730 mg, about 1740 mg, about 1750 mg, about 1760 mg, about 1770 mg, about 1780 mg, about 1790 mg, about 1800 mg, about 1810 mg, about 1820 mg, about 1830 mg, about 1840 mg, about 1850 mg, about 1860 mg, about 1870 mg, about 1880 mg, about 1890 mg, about 1900 mg, about 1910 mg, about 1920 mg, about 1930 mg, about 1940 mg, about 1950 mg, about 1960 mg, about 1970 mg, about 1980 mg, about 1990 mg, about 2000 mg, or even more. Methods of Manufacturing In one aspect, softgel capsules are made using a rotary die apparatus as described in U.S. Patent Nos. 5,459,983; 5,146,730; and 6,482,516, each of which are incorporated by reference herein for such teachings. Another embodiment described herein includes a process of manufacturing softgel capsules comprising the methods as described herein. The process includes preparing a gel mass composition comprising a film-forming, water-soluble polymer, one or more disintegrants, an appropriate plasticizer or co-solvent, and solvent, optionally, one or more viscosity modifying polymers; casting the gel mass into films or ribbons using heat-controlled drums or surfaces; and manufacturing a soft capsule comprising a matrix fill using rotary die technology. The thickness of the films or ribbons that form the soft capsule shell comprises from about 0.010 inches (≈0.254 mm) to about 0.050 inches (≈1.27 mm), including all integers within the specified range. The shell thickness can be about 0.010 inch (≈0.254 mm), about 0.015 inch (≈0.381 mm), about 0.02 in (≈0.508 mm), about 0.03 in (≈0.762 mm), about 0.04 in (≈1.02 mm), or about 0.05 in (≈1.27 mm). In one embodiment, the thickness comprises from about 0.02 inches (≈0.508 mm) to about 0.040 inches (≈1.02 mm). In one embodiment, the shell thickness is about 0.028 inches (≈0.711 mm). In another embodiment, the shell thickness is about 0.033 inches (≈0.838 mm). In another embodiment, the shell thickness is about 0.038 inches (≈0.965 mm). In one embodiment described herein, the soft capsule shell described herein, encapsulates a matrix fill as described herein. In another embodiment described herein, the soft capsule shell and encapsulated matrix fill comprises an outer dimension from about 2 oval to about 30 oval including all iterations of capsule size within the specified range (e.g., 2 oval, 3 oval, 4 oval, 5 oval, 6 oval, 7 oval, 8 oval, 10 oval, 12 oval, 16 oval, 20, or 30 oval). In another embodiment described herein, the soft capsule shell and encapsulated matrix fill comprises an outer dimension from about 2 round to about 28 round including all iterations of capsule size within the specified range (e.g., 2 round, 3 round, 4 round, 5 round, 6 round, 7 round, 8 round, 10 round, 12 round, 16 round, 20 round or 28 round). In another embodiment described herein, the soft capsule shell and encapsulated matrix fill comprises an outer dimension from about 2 oblong to about 22 oblong including all iterations of capsule size within the specified range (e.g., 2 oblong, 3 oblong, 4 oblong, 5 oblong, 6 oblong, 7 oblong, 8 oblong, 10 oblong, 11, oblong, 12 oblong, 14 oblong, 16 oblong, 20 oblong, or 22 oblong). Dimension specifications of soft capsules and tablets are known to those skilled in the art. See Remington’s Essentials of Pharmaceutics, Pharmaceutical Press Publishing Company, London, UK, 1stEdition, 2013, which is incorporated by reference herein for such teachings. In one non-limiting exemplary embodiment, the soft capsule can be manufactured by the following steps: (a) preparing a gel mass composition comprising one or more film-forming polymers, one or more disintegrants, one or more plasticizers or co-solvents, and one or more solvents to form a gel mass; optionally, the gel mass composition further comprises one or more viscosity modifying polymers. (b) heating the gel mass at 57–80 °C under vacuum for 15–30 min to create a homogenous and de-aerated gel mass; (c) ageing the homogenous and de-aerated gel mass 12–48 hr at 65–70 °C to create an aged gel mass; (d) casting the aged gel mass into films or ribbons using heat-controlled drums or surfaces; (e) transferring a homogenized fill solution to an encapsulation line; (f) encapsulating the homogenized fill solution within the gel mass films or ribbons using rotary dye encapsulation to create a capsule; (g) drying and finishing the capsule; (h) optionally, coating the capsule with a coating and drying; and (i) post processing and packaging. A flow chart for an exemplary method of manufacturing a rapid releasing softgel capsule, as described above, is provided in FIG.1. Additional processing aids that can be used during the manufacturing process are shown in Table 3. Nitrogen is used to purge oxygen from the gel mass. Medium chain triglycerides and lecithin are used as lubricants to prevent the gel ribbon from sticking to the spreader box and rotary die encapsulation machinery. Capsules are also lubricated to prevent sticking during post-manufacturing processing. Table 3. Exemplary Processing Aids Component Function Mass Range (mg) Nitrogen Oxygen purge – Medium Chain Triglycerides (MCT) Gelatin Ribbon Lubricant – 97% MCT & 3% Lecithin Capsule Lubricant – When softgel capsules are manufactured they are typically dried for a period of time. This permits water to evaporate from the capsule shell to increase rigidity and strength. A range of about 5–30% by mass of water from the shell can evaporate. Consequently, the relative mass percentages of the other shell components increase as water is lost to evaporation. In addition, when fills with low water are encapsulated, water from the capsule shell can migrate from the shell into the fill via osmosis. This can also contribute to water loss from the shell. Table 4 shows the masses of the fill, shell, and total capsule immediately after manufacturing and after drying (for an oil-filled capsule). Table 4. Finished Capsule Target Composition Capsule Components Mass (mg)* Total theoretical fill weight (prior to drying) – Total theoretical shell weight (prior to drying) – Total theoretical capsule weight (prior to drying) – Total theoretical fill weight (after drying) – Total theoretical shell weight (after drying) – Total theoretical capsule weight (after drying) – Mass percent difference in fill after drying –% Mass percent difference in shell after drying –% Mass percent difference in total capsule afer drying –% * Estimated based on capsules from a prototype batch. In some embodiments, rapid releasing softgel capsules may also be pre-stressed to enhance the release rate. Exemplary examples of pre-stressing including laser drilling, mechanical drilling, scoring, or other known means to pre-stress the gel capsule. In one embodiment, rapid releasing softgel capsules may be pre-stressed by laser drilling or other known means during manufacturing, regardless of the particular softgel capsule formulation or the fill formulation. In other embodiments, rapid releasing softgel capsules may be pre-stressed during manufacturing with a particular softgel capsule formulation as described herein. It is understood that gel reactors play an important role in the overall manufacturing process. It is responsible for mixing, blending, and dispersing highly viscous gels. High viscosity gels can be challenging to handle due to their thick consistency, which makes it difficult to achieve uniform mixing and dispersion. Specific types of gel reactors must be used to accommodate high viscosity gels, for example gel reactors with high shear mixing mechanisms. High shear mixing thus involves the use of specialized equipment that applies intense mechanical forces to break down the viscosity and create a homogeneous gel mass. This process ensures that all components of the formulation are thoroughly mixed and dispersed, resulting in a consistent and uniform gel. When dealing with high viscosity gels, it is possible that transferring the gel from the gel reactor to the gel holding tank can pose additional challenges. The thick consistency of the gel may make it difficult to transfer through a nozzle or piping system. In such cases, an additional pump, specifically a positive displacement pump, is often required. Positive displacement pumps are designed to handle viscous fluids and provide the necessary pressure to transfer the gel effectively. However, the inclusion of an additional pump can increase the overall cost of the manufacturing process. Decreasing viscosity is thus advantageous. Provided that one or more viscosity modifying polyme rs are included in the softgel capsule formation, it would allow easier mixing and transfer, eliminating the need for high shear mixing or additional pumps or requirements on the type of gel reactors used. Methods of Administration The dosage form can be administered, for example, 1×, 2×, 3×, 4×, 5×, 6× per day, or even more. One or more dosage forms can be administered, for example, for 1, 2, 3, 4, 5, 6, 7 days, or even longer. One or more dosage forms can be administered, for example, for 1, 2, 3, 4 weeks, or even longer. One or more dosage forms can be administered, for example, for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months, or even longer. One or more dosage forms can be administered until the patient, subject, mammal, mammal in need thereof, human, or human in need thereof, does not require treatment, prophylaxis, or amelioration of any disease or condition. The dosage form can be administered quaque die (QD), bis in die (BID), ter in die (TID), quater in die (QID) or in other dosing regimens, such as X capsules every Y hours, where X is the number of capsules and Y is the hourly interval. In one embodiment, the dosage form described herein is administered in multiple doses simultaneously. For example, two or more identical doses are administered at one time. In another embodiment, two or more different doses are administered at one time. Such dual or different simultaneous doses can be used to provide an effective amount of the pharmaceutical composition to a subject in need thereof. In another embodiment, the dosage forms as described herein can be administered with or without food. In one aspect, the dosage forms as described herein can be administered with food. In another aspect, the dosage forms as described herein can be administered without food. Kits and Packaging Another embodiment described herein is a kit for dispensing an oral pharmaceutical composition comprising at least one rapid releasing soft capsule and at least one receptacle comprising a tamper evident, moisture proof packaging comprising blister or strip packs, aluminum blister, transparent or opaque polymer blister with pouch, polypropylene tubes, colored blister materials, tubes, bottles, and bottles optionally containing a child-resistant feature, optionally comprising a desiccant, such as a molecular sieve or silica gel; and optionally, an insert comprising instructions or prescribing information for the active pharmaceutical ingredient. In one aspect, the tamper evident packaging comprises: bottles, film wrappers, blister or strip packs, bubble packs, heat shrink bands or wrappers, foil, paper, or plastic pouches, container mouth inner seals, tape seals, breakable caps, sealed metal tubes or plastic heat-sealed tubes, sealed cartons, aerosol containers, cans including metal and composite materials, or any combination thereof. The packaging may also contain a label, appropriate instructions for prescribing, instructions for use, warnings, or other appropriate information. In some embodiments, packaging may comprise the use of bottles and / or blisters having moisture barrier properties. In one aspect, high density polyethylene (HDPE) or aluminum bottles having moisture barrier properties may be used for packaging kits comprising softgel capsules as described herein. In some embodiments, packaging may further comprise the use of a desiccant. In one aspect, the dessicant may comprise a silica gel package, which is typically provided as a 1-gram packet. The use of dessicants and bottles and blisters having moisture barrier properties in packaging can help prevent the aggregation and nesting of softgels. One embodiment described herein is a rapid releasing softgel capsule formulation, the formulation comprising: about 15–60% by mass of one or more film-forming polymers; about 1– 30% by mass of one or more disintegrating agents; about 5–30% by mass of one or more plasticizers or co-solvents; and about 10–45% by mass of one or more solvents, optionally, about 1-20% by mass of one or more viscosity modifying polymers. In one aspect, the one or more film- forming polymers comprises gelatin, gelatin hydrolysates, collagen, carrageenans, or agars. In another aspect, the one or more film-forming polymers comprises gelatin having a Bloom value of about 50 Bloom to about 200 Bloom. In another aspect, the gelatin has a Bloom value of about 150 Bloom. In another aspect, the formulation comprises about 20–40% by mass of the one or more film-forming polymers. In another aspect, the one or more disintegrating agents comprises sodium starch glycolate, croscarmellose sodium, crospovidone, calcium silicate, magnesium aluminum silicate, or cross-linked alginic acid. In another aspect, the formulation comprises about 5–25% by mass of the one or more disintegrating agents. In another aspect, the formulation comprises about 8–12% by mass of the one or more disintegrating agents. In another aspect, the formulation comprises about 15–25% by mass of the one or more disintegrating agents. In another aspect, the one or more plasticizers or co-solvents comprises solutions of polyols, monosaccharides, disaccharides, oligosaccharides, blended hydrophilic molecules, glycerol, sorbitol, polyethylene glycols, or maltitol. In another aspect, the formulation comprises about 10– 20% by mass of the one or more plasticizers or co-solvents. In another aspect, the one or more solvents comprises water. In another aspect, the formation comprises about 1-20% by mass of one or more viscosity modifying polymers. The formulation of claim 1, further comprising one or more of colorants, opacifiers, flavors or sweeteners, humectants, preservatives, coatings, viscosity modifiers, fillers or bulking agents, active pharmaceutical ingredients, viscosity modifying polymers, or buffering salts and acids. In another aspect, the formulation comprises about 0.01– 10% by mass of one or more colorants comprising synthetic dyes, natural dyes, or a combination thereof. In another aspect, the formulation comprises about 0.01–1% by mass of one or more opacifiers comprising titanium dioxide, zinc oxide, calcium carbonate, or combinations thereof. In another aspect, the formulation comprises about 0.01–1% by mass of one or more flavors or sweeteners. In another aspect, the capsule ruptures within about 3–9 minutes in a USP Apparatus II at 37 °C. In another aspect, the capsule ruptures within about 5 minutes in a USP Apparatus II at 37 °C. Another embodiment described herein is a method for manufacturing a rapid releasing softgel capsule, the method comprising: preparing a gel mass composition comprising one or more film-forming polymers, one or more disintegrants, one or more plasticizers or co-solvents, and one or more solvents to form a gel mass; heating the gel mass to create a homogenous and de-aerated gel mass; ageing the homogenous and de-aerated gel mass to create an aged gel mass; casting the aged gel mass into films or ribbons using heat-controlled drums or surfaces; transferring a homogenized fill solution to an encapsulation line; encapsulating the homogenized fill solution within the gel mass films or ribbons using rotary dye encapsulation to create a capsule; drying and finishing the capsule; optionally, coating the capsule with a coating and drying; and post processing and packaging. In one aspect, the gel mass comprises: about 15–60% by mass of the one or more film-forming polymers; about 1–30% by mass of the one or more disintegrants; about 5–30% by mass of the one or more plasticizers or co-solvents; and about 10–45% by mass of the one or more solvents. In another aspect, heating the gel mass in step (b) comprises a temperature of about 57–80 °C under vacuum for about 15–30 minutes to create the homogenous and de-aerated gel mass. In another aspect, ageing the homogenous and de-aerated gel mass in step (c) comprises a temperature of about 65–70 °C for about 12–48 hours to create the aged gel mass. In another aspect, the capsule is pre-stressed to increase the rupture rate. Another embodiment described herein is a rapid releasing softgel capsule manufactured by any of the methods described herein. Another embodiment described herein is a pharmaceutical dosage form comprising a rapid releasing softgel capsule and a matrix fill comprising one or more active pharmaceutical ingredients, wherein the rapid releasing softgel capsule ruptures within about 3–9 minutes in a USP Apparatus II at 37 °C and releases the matrix fill comprising the one or more active pharmaceutical ingredients. In one aspect, the dosage form ruptures within about 5 minutes in a USP Apparatus II at 37 °C. In another aspect, the rapid releasing softgel capsule comprises: about 15–60% by mass of the one or more film-forming polymers; about 1–30% by mass of the one or more disintegrants; about 5–30% by mass of the one or more plasticizers or co-solvents; and about 10–45% by mass of the one or more solvents. Another embodiment described herein is a pharmaceutical dosage form comprising a rapid releasing softgel capsule and an encapsulated tablet comprising one or more active pharmaceutical ingredients, wherein the rapid releasing softgel capsule ruptures within about 3– 9 minutes in a USP Apparatus II at 37 °C and releases the encapsulated tablet comprising the one or more active pharmaceutical ingredients. In one aspect, the dosage form ruptures within about 5 minutes in a USP Apparatus II at 37 °C. In another aspect, the rapid releasing softgel capsule comprises: about 15–60% by mass of the one or more film-forming polymers; about 1– 30% by mass of the one or more disintegrants; about 5–30% by mass of the one or more plasticizers or co-solvents; and about 10–45% by mass of the one or more solvents. Another embodiment described herein is a method for rapidly delivering one or more active pharmaceutical ingredients to a subject in need thereof, the method comprising administering to the subject a pharmaceutical dosage form comprising a rapid releasing softgel capsule and a matrix fill comprising the one or more active pharmaceutical ingredients, wherein the rapid releasing softgel capsule ruptures within about 3–9 minutes following administration and releases the matrix fill comprising the one or more active pharmaceutical ingredients to the subject. In one aspect, the dosage form ruptures within about 5 minutes following administration. Another embodiment described herein is a method of treating a subject in need thereof with one or more active pharmaceutical ingredients, the method comprising administering to the subject a pharmaceutical dosage form comprising a rapid releasing softgel capsule and a matrix fill comprising the one or more active pharmaceutical ingredients, wherein the rapid releasing softgel capsule ruptures within about 3–9 minutes following administration and releases the matrix fill comprising the one or more active pharmaceutical ingredients to the subject. In one aspect, the dosage form ruptures within about 5 minutes following administration. It will be apparent to one of ordinary skill in the relevant art that suitable modifications and adaptations to the compositions, formulations, methods, processes, and applications described herein can be made without departing from the scope of any embodiments or aspects thereof. The compositions and methods provided are exemplary and are not intended to limit the scope of any of the specified embodiments. All of the various embodiments, aspects, and options disclosed herein can be combined in any variations or iterations. The scope of the compositions, formulations, methods, and processes described herein include all actual or potential combinations of embodiments, aspects, options, examples, and preferences herein described. The exemplary compositions and formulations described herein may omit any component, substitute any component disclosed herein, or include any component disclosed elsewhere herein. The ratios of the mass of any component of any of the compositions or formulations disclosed herein to the mass of any other component in the formulation or to the total mass of the other components in the formulation are hereby disclosed as if they were expressly disclosed. Should the meaning of any terms in any of the patents or publications incorporated by reference conflict with the meaning of the terms used in this disclosure, the meanings of the terms or phrases in this disclosure are controlling. Furthermore, the foregoing discussion discloses and describes merely exemplary embodiments. All patents and publications cited herein are incorporated by reference herein for the specific teachings thereof. Various embodiments and aspects of the inventions described herein are summarized by the following clauses: Clause 1. A rapid releasing softgel capsule formulation, the formulation comprising: about 15–60% by mass of one or more film-forming polymers; about 1–30% by mass of one or more disintegrating agents; about 5–30% by mass of one or more plasticizers or co-solvents; and about 10–45% by mass of one or more solvents. Clause 2. The formulation of clause 1, wherein the one or more film-forming polymers comprises gelatin, gelatin hydrolysates, collagen, carrageenans, or agars. Clause 3. The formulation of clause 1 or 2, wherein the one or more film-forming polymers comprises gelatin having a Bloom value of about 50 Bloom to about 200 Bloom. Clause 4. The formulation of any one of clauses 1–3, wherein the gelatin has a Bloom value of about 150 Bloom. Clause 5. The formulation of any one of clauses 1–4, wherein the formulation comprises about 20–40% by mass of the one or more film-forming polymers. Clause 6. The formulation of any one of clauses 1–5, wherein the one or more disintegrating agents comprises sodium starch glycolate, croscarmellose sodium, crospovidone, calcium silicate, magnesium aluminum silicate, or cross-linked alginic acid. Clause 7. The formulation of any one of clauses 1–6, wherein the formulation comprises about 5–25% by mass of the one or more disintegrating agents. Clause 8. The formulation of any one of clauses 1–7, wherein the formulation comprises about 8–12% by mass of the one or more disintegrating agents. Clause 9. The formulation of any one of clauses 1–8, wherein the formulation comprises about 15–25% by mass of the one or more disintegrating agents. Clause 10. The formulation of any one of clauses 1–9, wherein the one or more plasticizers or co-solvents comprises solutions of polyols, monosaccharides, disaccharides, oligosaccharides, blended hydrophilic molecules, glycerol, sorbitol, polyethylene glycols, or maltitol. Clause 11. The formulation of any one of clauses 1–10, wherein the formulation comprises about 10–20% by mass of the one or more plasticizers or co-solvents. Clause 12. The formulation of any one of clauses 1–11, wherein the one or more solvents comprises water. Clause 13. The formulation of any one of clauses 1–12, further comprising one or more of colorants, opacifiers, flavors or sweeteners, humectants, preservatives, coatings, viscosity modifiers, fillers or bulking agents, active pharmaceutical ingredients, or buffering salts and acids. Clause 14. The formulation of any one of clauses 1–13, wherein the formulation comprises about 0.01–10% by mass of one or more colorants comprising synthetic dyes, natural dyes, or a combination thereof. Clause 15. The formulation of any one of clauses 1–14, wherein the formulation comprises about 0.01–1% by mass of one or more opacifiers comprising titanium dioxide, zinc oxide, calcium carbonate, or combinations thereof. Clause 16. The formulation of any one of clauses 1–15, wherein the formulation comprises about 0.01–1% by mass of one or more flavors or sweeteners. Clause 17. The formulation of any one of clauses 1–16, wherein the capsule ruptures within about 3–9 minutes in a USP Apparatus II at 37 °C. Clause 18. The formulation of any one of clauses 1–17, wherein the capsule ruptures within about 5 minutes in a USP Apparatus II at 37 °C. Clause 19. A method for manufacturing a rapid releasing softgel capsule, the method comprising: (a) preparing a gel mass composition comprising one or more film-forming polymers, one or more disintegrants, one or more plasticizers or co-solvents, and one or more solvents to form a gel mass; (b) heating the gel mass to create a homogenous and de-aerated gel mass; (c) ageing the homogenous and de-aerated gel mass to create an aged gel mass; (d) casting the aged gel mass into films or ribbons using heat-controlled drums or surfaces; (e) transferring a homogenized fill solution to an encapsulation line; (f) encapsulating the homogenized fill solution within the gel mass films or ribbons using rotary dye encapsulation to create a capsule; (g) drying and finishing the capsule; (h) optionally, coating the capsule with a coating and drying; and (i) post processing and packaging. Clause 20. The method of clause 19, wherein the gel mass comprises: about 15–60% by mass of the one or more film-forming polymers; about 1–30% by mass of the one or more disintegrants; about 5–30% by mass of the one or more plasticizers or co-solvents; and about 10–45% by mass of the one or more solvents. Clause 21. The method of clause 19 or 20, wherein heating the gel mass in step (b) comprises a temperature of about 57–80 °C under vacuum for about 15–30 minutes to create the homogenous and de-aerated gel mass. Clause 22. The method of any one of clauses 19–21, wherein ageing the homogenous and de-aerated gel mass in step (c) comprises a temperature of about 65–70 °C for about 12– 48 hours to create the aged gel mass. Clause 23. The method of any one of clauses 19–22, wherein the capsule is pre-stressed to increase the rupture rate. Clause 24. A rapid releasing softgel capsule manufactured by the method of any one of clauses 19–23. Clause 25. A pharmaceutical dosage form comprising a rapid releasing softgel capsule and a matrix fill comprising one or more active pharmaceutical ingredients, wherein the rapid releasing softgel capsule ruptures within about 3–9 minutes in a USP Apparatus II at 37 °C and releases the matrix fill comprising the one or more active pharmaceutical ingredients. Clause 26. The pharmaceutical dosage form of clause 25, wherein the dosage form ruptures within about 5 minutes in a USP Apparatus II at 37 °C. Clause 27. The pharmaceutical dosage form of clause 25 or 26, wherein the rapid releasing softgel capsule comprises: about 15–60% by mass of the one or more film-forming polymers; about 1–30% by mass of the one or more disintegrants; about 5–30% by mass of the one or more plasticizers or co-solvents; and about 10–45% by mass of the one or more solvents. Clause 28. A pharmaceutical dosage form comprising a rapid releasing softgel capsule and an encapsulated tablet comprising one or more active pharmaceutical ingredients, wherein the rapid releasing softgel capsule ruptures within about 3–9 minutes in a USP Apparatus II at 37 °C and releases the encapsulated tablet comprising the one or more active pharmaceutical ingredients. Clause 29. The pharmaceutical dosage form of clause 28, wherein the dosage form ruptures within about 5 minutes in a USP Apparatus II at 37 °C. Clause 30. The pharmaceutical dosage form of clause 28 or 29, wherein the rapid releasing softgel capsule comprises: about 15–60% by mass of the one or more film-forming polymers; about 1–30% by mass of the one or more disintegrants; about 5–30% by mass of the one or more plasticizers or co-solvents; and about 10–45% by mass of the one or more solvents. Clause 31. A method for rapidly delivering one or more active pharmaceutical ingredients to a subject in need thereof, the method comprising administering to the subject a pharmaceutical dosage form comprising a rapid releasing softgel capsule and a matrix fill comprising the one or more active pharmaceutical ingredients, wherein the rapid releasing softgel capsule ruptures within about 3–9 minutes following administration and releases the matrix fill comprising the one or more active pharmaceutical ingredients to the subject. Clause 32. The method of clause 31, wherein the dosage form ruptures within about 5 minutes following administration. Clause 33. A method of treating a subject in need thereof with one or more active pharmaceutical ingredients, the method comprising administering to the subject a pharmaceutical dosage form comprising a rapid releasing softgel capsule and a matrix fill comprising the one or more active pharmaceutical ingredients, wherein the rapid releasing softgel capsule ruptures within about 3–9 minutes following administration and releases the matrix fill comprising the one or more active pharmaceutical ingredients to the subject. Clause 34. The method of clause 33, wherein the dosage form ruptures within about 5 minutes following administration. EXAMPLES Example 1 Exemplary softgel shell compositions were prepared as shown in Table 5. Table 5. Experimental Rapid Release Capsule Shell Gel Formulation Component Function Application Mass Batch (kg) Percentage (%) Gelatin 9.1038.9Sodium starch glycolate Super-disintegrant 2.008.6Glycerin Plasticizer 1.16 5.0 Maltitol (hydrogenated glucose syrup; e.g., Lycasin®) Plasticizer / Cosolvent 2.80 12.0 Purified Water Solvent 6.9429.7Extra Purified Water Solvent 1.395.9Theoretical Total 23.39 100 A total of four protype softgel batches using 150 Bloom bovine gelatin were manufactured using sodium starch glycolate (SSG) at a mass percentage of 8.6% (w / w) based on the gelatin formulation. Capsules were manufactured using 8.6% SSG with varying gelatin ribbon thickness from 0.028–0.035 inches (0.7112–0.889 mm) (4 lots) and 2 lots utilizing ribbon thickness between 0.032–0.035 inches (0.8128–0.889 mm) using gelatin aged ~24–48 hours. In addition, three control lots of gelatin were manufactured without SSG, utilizing gelatin ribbon thickness from 0.032–0.035 inches (0.8128–0.889 mm). Each of the lots listed used a fill of Orange Organic Essential Oil (Sweet). Example 2 Samples of the softgel capsules prepared in Example 1 were analyzed for disintegration / rupture using USP Disintegration Method !701" at 37 °C and 22 °C. The rupture test was performed according to USP General Chapter !2040". Six soft-shell capsules were tested directly in 500 mL of degassed purified water. The test was performed at 37 ± 0.5 °C or 22 ± 0.5 °C at 50 RPM using USP Apparatus II (Paddle Apparatus; Distek). The capsules were observed, and the time of shell rupture was recorded. The rupture test continued until all samples had ruptured or was aborted at 30 min. Data are shown in Tables 6–7, 8–9, and FIG.2–3 for the 37 °C and 22 °C experiments, respectively. Table 6. Rupture Time of Experimental Samples at 37 °C (min) Ribbon Initial Final Sample Width Temp Temp V1 V2 V3 V4 V5 V6 Avg (in) (°C) (°C) S23-236 0.028 36.7 36.6 6 4 6 4 3 9 5 S23-237 0.032 36.9 36.9 4 3 6 3 6 7 5 S23-238 0.035 36.7 36.6 7 7 6 7 7 4 6 S23-239 0.024 36.6 36.9 6 5 3 5 4 4 4 S23-240 0.028 36.6 36.6 6 5 7 2 7 4 5 S23-241 0.032 36.8 36.7 8 4 8 4 7 6 6 S23-242 0.035 36.5 36.7 6 5 5 4 7 5 5 Table 7. Rupture Time of Control Samples at 37 °C (min) Ribbon Initial Final Sample Width Temp Temp V1 V2 V3 V4 V5 V6 Avg (in) (°C) (°C) S23-2620.035 36.7 36.5 11 12 11 7 10 9 9 S23-2630.032 36.9 36.6 9 10 9 11 10 11 10 S23-2640.024 36.9 36.7 13 11 10 5 6 7 8 Table 8. Rupture Time of Experimental Samples at 22 °C (min) Sample Ribbon Initial Final Width (in) Temp (°C) Temp (°C) V1 V2 Avg S23-236 0.028 21.7 21.7 12 12 12 S23-237 0.032 21.5 21.3 16 17 16 S23-238 0.035 21.9 21.8 15 17 16 S23-239 0.024 21.7 21.7 11 10 11 S23-240 0.028 21.5 21.2 14 15 14 S23-241 0.032 21.8 21.8 20 25 23 S23-242 0.035 21.5 21.6 7 7 7 Table 9. Rupture Time of Control Samples at 22 °C (min) Sample Ribbon Initial Final Width (in) Temp (°C) Temp (°C) V1 V2 Avg The following rapid release capsules were prepared containing either an acetaminophen or medium chain triglycerides fill with various amounts of a disintegrant (10–29.5% sodium starch glycolate) incorporated into the capsule shell. Capsule fills are shown in Tables 10–11. Table 10. Acetaminophen (APAP) Suspension Fill Composition Ingredient Quantity (g) Acetaminophen (APAP), USP 2000 Polyethylene Glycol 400 (PEG 400), NF 1420 Polyethylene Glycol 600 (PEG 600), NF 444 Purified water 80.00 Propylene glycol, USP 24 Povidone K-30, USP 8 Total 3976 The acetaminophen fill was prepared under yellow light and stored at ambient conditions under nitrogen. The polyethylene glycol 600 was pre-heated to 60 °C, transferred to a mixing vessel and cooled and maintained at 42 °C to prevent solidification. Polyethylene glycol 400, Povidone K-30 and purified water were added, and the mixture stirred and heated at 40 °C until a clear solution was obtained. Acetaminophen was added and mixed. The resulting mixture was de-aerated and maintained at 34.5 °C. The mixture was de-aerated and transferred to a holding tank and stored under nitrogen at ambient temperature until encapsulation. Table 11. Medium Chain Triglyceride Fill Composition Ingredient Quantity (g) Medium Chain Triglycerides (MCT), USP / NF 2000 D&C Red #27 2 Total 2000 The medium chain triglycerides fill was prepared by combining the medium chain triglycerides in a mixing tank. The mixture was de-aerated and transferred to a holding tank and stored under nitrogen at ambient temperature until encapsulation. Rapid release capsule compositions are shown in Tables 12–15, followed by the gel mass preparation for each formulation. Table 12. Rapid Release Gel Mass Composition (10% SSG) Component Function Application Batch (kg) Gelatin 150 Bloom LB Film-forming polymer 9.10 Glycerin Plasticizer 1.16 Maltitol (e.g., Lycasin®) Plasticizer / Cosolvent 2.80 Purified Water Solvent 6.94 Sodium Starch Glycolate (SSG) Super-disintegrant 2.00 Extra Purified Water Solvent 1.39 Theoretical Total 23.39 10%SSG Gel Mass Preparation The shell ingredients gelatin, glycerin, lycasin, sodium starch glycolate and purified water were blended under mild agitation in a pre-heated jacket gel tank at 50 °C. The mixture was cooked for 2 hr at 50–70 °C under vacuum and aged overnight at 70 °C. The gel mass was clear, free from air bubbles, and free of particulates. The gel mass was maintained at 70 °C prior to and during encapsulation. Table 13. Rapid Release Gel Mass Composition (15% SSG) Component Function Application Batch (kg) Gelatin 150 Bloom LB Film-forming polymer 9.10 Glycerin Plasticizer 1.16 Maltitol (e.g., Lycasin®) Plasticizer / Cosolvent 2.80 Purified Water Solvent 6.94 Sodium Starch Glycolate (SSG) Super-disintegrants 3.00 Extra Purified Water Solvent 1.39 Theoretical Total 24.39 15% SSG Gel Mass Preparation The shell ingredients gelatin, glycerin, lycasin, sodium starch glycolate and purified water were blended in a jacket heated gel tank at 40 °C. The gel mass was formed by heating for 2 hr at 70–75 °C under vacuum and aged overnight at 72–74 °C. The gel mass was clear, free from air bubbles, and free of particulates. The gel mass was maintained at 72–74 °C prior to and during encapsulation. Table 14. Rapid Release Gel Mass Composition (20% SSG) Component Function Application Batch (kg) Gelatin 150 Bloom LB Film-forming polymer 9.10 Glycerin Plasticizer 1.16 Maltitol (e.g., Lycasin®) Plasticizer / Cosolvent 2.80 Purified Water Solvent 6.94 Sodium Starch Glycolate (SSG) Super-disintegrant 4.00 Extra Purified Water Solvent 1.39 Theoretical Total 25.39 20% SSG Gel Mass Preparation The shell ingredients gelatin, glycerin, lycasin, sodium starch glycolate and purified water were blended in a jacket heated gel tank. The gel mass was formed by heating for 2 hr at 60– 70 °C under vacuum and aged overnight at 70–72°C. The gel mass was clear, free from air bubbles, and free of particulates. The gel mass was maintained at 70–72 °C prior to and during encapsulation. Table 15. Rapid Release Gel Mass Composition (29.5% SSG) Component Function Application Batch (kg) Gelatin 150 Bloom LB Film-forming polymer 9.10 Glycerin Plasticizer 1.16 Maltitol (e.g., Lycasin®) Plasticizer / Cosolvent 2.80 Purified Water Solvent 6.94 Sodium Starch Glycolate (SSG) Super-disintegrant 5.90 Extra Purified Water Solvent 1.39 Theoretical Total 27.29 29.5% SSG Gel Mass Preparation The shell ingredients gelatin, glycerin, lycasin, sodium starch glycolate and purified water were blended in a pre-heated jacket gel tank at 55°C. The gel mass was formed by heating for 2 hr at 55–72 °C under vacuum and aged overnight at 70 °C. The gel mass was clear, free from air bubbles and free of particulates. The gel mass was maintained at 70 °C prior to and during encapsulation. Capsules were manufactured using rotary die encapsulation. A summary of the production results is shown in Table 16. Successful capsules were manufactured from formulations containing 10%, 15% and 20% sodium starch glycolate (SSG). The capsule formulation containing 20% SSG was very viscous, but capsules were successfully manufactured. Capsule formulations containing 29.5% SSG were not able to be successfully manufactured because the capsules would not seal. Table 16. Manufacturing Summary SSG (%) Fill Materials Fill Weight Capsule Size Strength Status Example 4 Capsules containing 10%, 15% and 20% sodium starch glycolate (SSG) as prepared in Example 3 were tested for rupture and comparative dissolution against a control capsule. Rupture Samples of the acetominophen softgel capsules prepared in Example 3 were analyzed for disintegration / rupture using USP Disintegration Method !701" at 37 °C. The rupture test was performed according to USP General Chapter !2040". Six soft-shell capsules were tested directly in 500 mL of degassed purified water. The test was performed at 37 ± 0.5 °C at 100 RPM using USP Apparatus II (Paddle Apparatus; Distek). The capsules were observed, and the time of shell rupture was recorded. The rupture test continued until all samples had ruptured or was aborted at 30 min. Data are shown in Table 17, and FIG.4. Table 17. Rupture Data (Paddle) Experiment 10% SSG 15% SSG 20% SSG 1 5 6 5 2 5 5 5 3 6 5 4 4 6 4 5 5 6 6 3 6 5 4 6 Avg. 5.5 5 5 Comparative Dissolution Samples of the acetominophen softgel capsules prepared in Example 3 were analyzed for dissolution using USP Dissolution Method !711" with Apparatus II (Paddle Apparatus) at a speed 100 RPM at 37 °C in suitable degassed media (0.1 N HCl) at pH ~1.2. The dissolution data is shown in Table 18 and FIG. 5A. Table 18. Comparative Dissolution Data Time (min) Control 10% SSG 15% SSG 20% SSG 5 0.010 0.006 0.024 0.074 10 59.1 52.2 62.0 50.5 15 88.2 83.2 84.4 87.2 20 93.7 89.2 90.5 94.2 30 96.4 94.8 98.0 98.1 45 98.2 97.9 101.2 100.9 The acetominophen control appeared to have shell cross linking issues. In order to verify the dissolution profile of the control, a dissolution experiment was performed with enzymes (pepsin) present in the dissolution media (0.1 N HCl; pH ~1.2). Data are shown in Table 19 and FIG. 5B. This experiment shows that the control dissolution was practically the same in normal media as in media with enzymes. Table 19. Acetominophen Control – Normal Media vs. Media + Enzyme (Paddle) Time (min) Normal Dissolution Dissolution + Enzymes 5 0.013 0.007 10 1.5 1.0 15 6.4 5.1 20 12.0 11.0 30 22.8 23.0 45 37.2 39.2 With respect to the above embodiments, aspects, examples, viscosity modifying polymers can be incorporated as shown in the following exemplary formulations in Table 20. In each formulation, PVP serving as the viscosity modifying polymer is added, and mass % of the other excipients are adjusted accordingly. Table 20. PVP Examples Mass % (0%) (5%) (10%) (15%) Lycasin1.10.5 0.5 0.5 Sorbitol Sorbitan00 0 0 Water3.33.5 3.5 3.5 Sodium Starch Glycolate1.61.5 1.5 1.5 PVP00.5 1 1.5 Total1010 10 10 Table 21 Capsule Shell Shell Rupture Disintegration

Claims

CLAIMS What is claimed:

1. A rapid releasing softgel capsule formulation, the formulation comprising: about 15–60% by mass of one or more film-forming polymers; about 1–30% by mass of one or more disintegrating agents; about 5–30% by mass of one or more plasticizers or co-solvents; and about 10–45% by mass of one or more solvents.

2. The formulation of claim 1, wherein the one or more film-forming polymers comprises gelatin, gelatin hydrolysates, collagen, carrageenans, or agars.

3. The formulation of claim 1 or 2, wherein the one or more film-forming polymers comprises gelatin having a Bloom value of about 50 Bloom to about 200 Bloom.

4. The formulation of claim 3, wherein the gelatin has a Bloom value of about 150 Bloom.

5. The formulation of any preceding claim, wherein the formulation comprises about 20–40% by mass of the one or more film-forming polymers.

6. The formulation of any preceding claim, wherein the one or more disintegrating agents comprises sodium starch glycolate, croscarmellose sodium, crospovidone, calcium silicate, magnesium aluminum silicate, or cross-linked alginic acid.

7. The formulation of any preceding claim, wherein the formulation comprises about 5–25% by mass of the one or more disintegrating agents.

8. The formulation of claim 7, wherein the formulation comprises about 8–12% by mass of the one or more disintegrating agents.

9. The formulation of claim 7, wherein the formulation comprises about 15–25% by mass of the one or more disintegrating agents.

10. The formulation of any preceding claim, wherein the one or more plasticizers or co- solvents comprises solutions of polyols, monosaccharides, disaccharides, oligosaccharides, blended hydrophilic molecules, glycerol, sorbitol, polyethylene glycols, or maltitol.

11. The formulation of any preceding claim, wherein the formulation comprises about 10–20% by mass of the one or more plasticizers or co-solvents.

12. The formulation of any preceding claim, wherein the one or more solvents comprises water.

13. The formulation of any preceding claim, further comprising one or more of colorants, opacifiers, flavors or sweeteners, humectants, preservatives, coatings, viscosity modifiers, fillers or bulking agents, active pharmaceutical ingredients, viscosity modifying polymers, or buffering salts and acids.

14. The formulation of claim 13, wherein the formulation comprises about 0.01–10% by mass of one or more colorants comprising synthetic dyes, natural dyes, or a combination thereof.

15. The formulation of claim 13, wherein the formulation comprises about 0.01–1% by mass of one or more opacifiers comprising titanium dioxide, zinc oxide, calcium carbonate, or combinations thereof.

16. The formulation of claim 13, wherein the formulation comprises about 0.01–1% by mass of one or more flavors or sweeteners.

17. The formulation of any preceding claim, further comprising about 1–20% by mass of one or more viscosity modifying polymers.

18. The formulation of claim 17, wherein the formulation comprises about 5–15% by mass of the one or more viscosity modifying polymers.

19. The formulation of claim 17, wherein the formulation comprises about 10% by mass of the one or more viscosity modifiers.

20. The formulation of claims 17 to 19, wherein the one or more viscosity modifying polymers comprising hydroxypropyl-methylcellulose, polyvinyl-pyrrolidone, polyvinyl alcohol, and dextran.

21. The formulation of any preceding claim, wherein the capsule ruptures within about 3–9 minutes at 37 °C.

22. The formulation of any preceding claim, wherein the capsule ruptures within about 5 minutes at 37 °C.

23. A method for manufacturing a rapid releasing softgel capsule, the method comprising: (a) preparing a gel mass composition comprising one or more film-forming polymers, one or more disintegrants, one or more plasticizers or co-solvents, and one or more solvents to form a gel mass; (b) heating the gel mass to create a homogenous and de-aerated gel mass; (c) ageing the homogenous and de-aerated gel mass to create an aged gel mass; (d) casting the aged gel mass into films or ribbons using heat-controlled drums or surfaces; (e) transferring a homogenized fill solution to an encapsulation line; (f) encapsulating the homogenized fill solution within the gel mass films or ribbons using rotary dye encapsulation to create a capsule; (g) drying and finishing the capsule; (h) optionally, coating the capsule with a coating and drying; and (i) post processing and packaging.

24. The method of claim 23, wherein the preparing a gel mass composition to form the gel mass further comprising about 1-20% by mass of one or more viscosity modifying polymers.

25. The method of claim 23, wherein the gel mass comprises: about 15–60% by mass of the one or more film-forming polymers; about 1–30% by mass of the one or more disintegrants; about 5–30% by mass of the one or more plasticizers or co-solvents; andabout 10–45% by mass of the one or more solvents.

26. The method of claims 23 to 25, wherein heating the gel mass in step (b) comprises a temperature of about 57–80 °C under vacuum for about 15–30 minutes to create the homogenous and de-aerated gel mass.

27. The method of claims 23 to 26, wherein ageing the homogenous and de-aerated gel mass in step (c) comprises a temperature of about 65–70 °C for about 12–48 hours to create the aged gel mass.

28. The method of claims 23 to 27, wherein the capsule is pre-stressed to increase the rupture rate.

29. A rapid releasing softgel capsule manufactured by the method of claims 23 to 28.

30. A pharmaceutical dosage form comprising a rapid releasing softgel capsule and a matrix fill comprising one or more active pharmaceutical ingredients, wherein the rapid releasing softgel capsule ruptures within about 3–9 minutes at 37 °C and releases the matrix fill comprising the one or more active pharmaceutical ingredients.

31. The pharmaceutical dosage form of claim 30, wherein the dosage form ruptures within about 5 minutes at 37 °C.

32. The pharmaceutical dosage form of claim 30 or 31, wherein the rapid releasing softgel capsule comprises: about 15–60% by mass of one or more film-forming polymers; about 1–30% by mass of one or more disintegrants; about 5–30% by mass of one or more plasticizers or co-solvents; and about 10–45% by mass of one or more solvents.

33. The pharmaceutical dosage form of claim 32, further comprises: about 1–20% by mass of one or more viscosity modifying polymers.

34. A pharmaceutical dosage form comprising a rapid releasing softgel capsule and an encapsulated tablet comprising one or more active pharmaceutical ingredients, whereinthe rapid releasing softgel capsule ruptures within about 3–9 minutes at 37 °C and releases the encapsulated tablet comprising the one or more active pharmaceutical ingredients.

35. The pharmaceutical dosage form of claim 34, wherein the dosage form ruptures within about 5 minutes at 37 °C.

36. The pharmaceutical dosage form of claim 34 or 35, wherein the rapid releasing softgel capsule comprises: about 15–60% by mass of the one or more film-forming polymers; about 1–30% by mass of the one or more disintegrants; about 5–30% by mass of the one or more plasticizers or co-solvents; and about 10–45% by mass of the one or more solvents.

37. The pharmaceutical dosage form of claim 36, wherein the rapid releasing softgel capsule further comprises: about 1–20% by mass of one or more viscosity modifying polymers.

38. A method for rapidly delivering one or more active pharmaceutical ingredients to a subject in need thereof, the method comprising administering to the subject a pharmaceutical dosage form comprising a rapid releasing softgel capsule and a matrix fill comprising the one or more active pharmaceutical ingredients, wherein the rapid releasing softgel capsule ruptures within about 3–9 minutes following administration and releases the matrix fill comprising the one or more active pharmaceutical ingredients to the subject.

39. The method of claim 38, wherein the dosage form ruptures within about 5 minutes following administration.

40. A method of treating a subject in need thereof with one or more active pharmaceutical ingredients, the method comprising administering to the subject a pharmaceutical dosage form comprising a rapid releasing softgel capsule and a matrix fill comprising the one or more active pharmaceutical ingredients, wherein the rapid releasing softgel capsule ruptures within about 3–9 minutes following administration and releases the matrix fill comprising the one or more active pharmaceutical ingredients to the subject.

41. The method of claim 40, wherein the dosage form ruptures within about 5 minutes following administration.

Images